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as the target of rapamycin complex 1 (TORC1), to downstream chromatin modifying enzymes. These
enzymes impact the gene regulatory process through altered histone post-translation modifications,
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(H3K56ac), almost nothing is known about how the complex functions in this regard. In this report, we
demonstrate that inhibition of TORC1 results in a site-specific reduction in acetylation on N-terminal
residues of both histone H3 and H4. This effect is dependent on sirtuin histone deacetylases (HDACs), as
inactivation of these enzymes, specifically Hst4, rescues the acetylation defect. We also find that this
sirtuin-mediated deacetylation response requires a functional protein phosphatase 6 complex (PP6). PP6
is under direct negative regulation of TORC1, and relief of this inhibition initiates a rapid cytoplasmic to
nuclear redistribution of Hst4 which correlates temporally with our observed loss of histone acetylation.
The nuclear accumulation of Hst4 precedes an increase in Hst4 protein levels that occurs due to a
reduction in Hst4 turnover. Notably, deletion of a subset of sirtuins (hst3Δ or hst4Δ) rescued the
sensitivity of a non-essential TORC1 mutant (tco89Δ) to an array of TORC1 inhibitors. This result
suggests the link between TORC1 and acetylation may play an essential role in cell cycle regulation and
the DNA damage response. We further evaluated whether these TORC1-mediated acetylation marks
contribute to the chromatin association of high mobility group proteins (HMGs). And while
TORC1-dependent displacement of the HMGs coincides with vacuolar acidification, hyperactivation of
TORC1, and significant cell death, it appears to occur independently of TORC1’s regulation of Hst4. We
conclude by investigating mitochondrial function in a tco89Δ mutant and mapping the functional
domains of Tco89 necessary to sustain TORC1 activity and respond to extracellular stress.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Biomedical Sciences

Research Advisor
Ronald N. Laribee

Keywords
Chromatin, Epigenetics, Histone acetylation, Sirtuins, Sit4, Target of Rapamycin

Subject Categories
Medical Biochemistry | Medical Cell Biology | Medical Genetics | Medical Sciences | Medicine and Health
Sciences
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/408

Environmental Signaling through the Target of Rapamycin
Complex 1 (TORC1) and the Regulation of Epigenetic Mechanisms

A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree of
Doctor of Philosophy
From The University of Tennessee

By
Jason J. Workman
December 2016

Portions of Chapter 3 © 2016 by Genetics Society of America.
All other material © 2016 by Jason J. Workman.
All rights reserved.

ii

DEDICATION
This work is dedicated to my loving wife, for continually reminding me what I’m capable
of, and for giving me something to look forward to at the end of the day.

iii

ACKNOWLEDGEMENTS
We would like to acknowledge the people who made this work, and my
matriculation through The University of Tennessee Health Science Center, possible.
First, I want to thank my fantastic Dissertation Committee, Dr. Larry Pfeffer, Dr.
Sunny Wu, Dr. Mondira Kundu and Dr. Janet Partridge, for their thoughtful reading of
this dissertation and guidance throughout the process. Next, my track director Dr. Tiffany
Seagroves and program director Dr. Ren Ostrom, for helping me to stay on top of all the
courses and paperwork necessary to complete the process. Additionally, I have to
mention the great group of people in the Graduate Health Sciences and Pathology offices,
particularly Ms. Barbara Frederick, Ms. Felicia Washington, Ms. Elizabeth Webb, and
CGHS dean Dr. Don Thomason.
We also would like to recognize Dr. Dan Klionsky (University of Michigan) for
providing us with the Tap42 temperature sensitive plasmids, and Dr. Mary Miller
(Rhodes College) for assisting with tetrad dissections.
Lastly, I want to thank my colleagues in the Laribee Laboratory. Dr. Hongfeng
Chen for providing me with great ideas and feedback throughout the process (and for
teaching me a little Chinese), and my mentor Dr. Nick Laribee, who has my sincere
gratitude for taking me in as his first student trainee and providing an environment that
allowed me to explore my potential and become the scientist that I am today. My work in
the Laribee Laboratory was supported by funding from the American Heart Association
and the National Institute of Health.

iv

ABSTRACT
The gene expression profile of a eukaryotic cell is responsive to a variety of extracellular
stimuli, including nutrient availability, which allows cells to toggle between anabolism
and catabolism based on the favorability of their environment. Much of this information
is relayed through signaling complexes, such as the target of rapamycin complex 1
(TORC1), to downstream chromatin modifying enzymes. These enzymes impact the gene
regulatory process through altered histone post-translation modifications, changes in
chromatin structure, and docking of chromatin regulatory complexes. Yet, despite
preliminary studies suggesting that TORC1 affects epigenetic mechanisms, including
histone H3 lysine 56 acetylation (H3K56ac), almost nothing is known about how the
complex functions in this regard. In this report, we demonstrate that inhibition of TORC1
results in a site-specific reduction in acetylation on N-terminal residues of both histone
H3 and H4. This effect is dependent on sirtuin histone deacetylases (HDACs), as
inactivation of these enzymes, specifically Hst4, rescues the acetylation defect. We also
find that this sirtuin-mediated deacetylation response requires a functional protein
phosphatase 6 complex (PP6). PP6 is under direct negative regulation of TORC1, and
relief of this inhibition initiates a rapid cytoplasmic to nuclear redistribution of Hst4
which correlates temporally with our observed loss of histone acetylation. The nuclear
accumulation of Hst4 precedes an increase in Hst4 protein levels that occurs due to a
reduction in Hst4 turnover. Notably, deletion of a subset of sirtuins (hst3Δ or hst4Δ)
rescued the sensitivity of a non-essential TORC1 mutant (tco89Δ) to an array of TORC1
inhibitors. This result suggests the link between TORC1 and acetylation may play an
essential role in cell cycle regulation and the DNA damage response. We further
evaluated whether these TORC1-mediated acetylation marks contribute to the chromatin
association of high mobility group proteins (HMGs). And while TORC1-dependent
displacement of the HMGs coincides with vacuolar acidification, hyperactivation of
TORC1, and significant cell death, it appears to occur independently of TORC1’s
regulation of Hst4. We conclude by investigating mitochondrial function in a tco89Δ
mutant and mapping the functional domains of Tco89 necessary to sustain TORC1
activity and respond to extracellular stress.
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CHAPTER 1.

INTRODUCTION

Histone Proteins and Chromatin Organization
The histone family of DNA packaging proteins is comprised of four isoforms:
H2A, H2B, H3 and H4. Each histone consists of a globular core and a pair of N- and Cterminal tails. All of the core histones exist as heterodimers of H2A/H2B or H3/H4, and
assembly of four of these heterodimers (two of each) results in formation of an octameric
structure collectively known as the nucleosome [1, 2]. Approximately 146 base pairs of
DNA are wound around each nucleosome, resulting in the “beads on a string” structure,
noted initially in early electron microscopy analyses of intact chromatin [3]. From there,
interactions between the nucleosomes themselves produce a more compacted form of
chromatin known as the 30 nm fiber. Additional higher order folding and packaging
condenses the 30 nm fiber even further to ultimately form chromosomes (Figure 1-1).
The Epigenome
The epigenome consists of a heritable set of highly complex histone posttranslation modifications, including acetylation, methylation, phosphorylation and
ubiquitination, which essentially establish a secondary layer of genetic information that is
stored above the chromatin. These epigenetic moieties occur predominantly on the Nterminal tails of the histones (Figure 1-2), where they function to coordinate a multitude
of chromatin-based processes; most notably, enabling changes to an organism’s
phenotype through adjustments in gene expression rather than alterations to the genotype.
Methylation of lysines and arginines on the histone tails has a very context specific effect
on transcription, which is most often coordinated through mediating the association of
methyl-binding proteins (i.e. Tudor domains, MBT domains, PHD domains,
chromodomains, and WD proteins) [4-11]. On the other hand, acetylation status of these
residues impacts the availability of the histone’s positively charged amino groups to bind
to the negatively charged DNA backbone. Specifically, increased acetylation results in a
more open and transcriptionally accessible chromatin state, while reduction in these
marks promotes a more heterochromatic and transcriptionally occlusive environment
(Figure 1-3). Intriguingly, histone acetylation at the ribosomal protein (RP) genes and the
ribosomal DNA (rDNA) has been shown to be responsive to signaling through nutrient
sensing complexes [12, 13]. This suggests that epigenetic mechanisms could coordinate
changes in gene expression in response to environmental nutrient availability. Despite a
recent swell of scientific and mainstream interest, there are some who still believe the
importance of the histone code and transgenerational epigenetic inheritance has been
overstated [14-19].

1

Figure 1-1. Cartoon representation of chromatin packaging.
DNA is spooled around the nucleosomes to form a loosely condensed, 11 nm fiber,
sometimes referred to as the “beads on a string” configuration. Nucleosomal interactions
drive additional levels of chromatin packaging, ultimately leading to the formation of
chromosomal DNA. See text for more details. Reprinted with permission [20]. DNA
Packaging - Shmoop Biology. 2008 [cited 2016 May 11]; Available from:
http://www.shmoop.com/dna/dna-packaging.html.

2

Figure 1-2. Schematic of the nucleosome.
The nucleosome is a histone octamer complex which consists of two heterodimers of
both H2A/H2B and H3/H4. The most topical post-translation modifications on the Nterminal tails of each histone are denoted.

3

Figure 1-3. Transcriptional availability of DNA is mediated by the epigenetic
modifications of histones.
Cartoon representation of the dynamic effects acetylation and methylation can have on
chromatin packaging, and subsequently, the accessibility of particular regions of DNA
for efficient gene transcription. Reprinted with permission [20]. DNA Packaging Shmoop Biology. 2008 [cited 2016 May 11]; Available from:
http://www.shmoop.com/dna/dna-packaging.html.
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Advantages of the S. cerevisiae Model System for Epigenetic Studies
The study of chromatin, particularly at single nucleosome resolution, proves very
challenging in most models or cell lines due to the multicopy nature of the core histone
genes. As an example, human cells have 15 copies of the H3 gene, encoding canonical
H3 and two additional H3 sequence variants [21, 22]. This high level of redundancy
makes probing the specific chromatin contributions of individual histone amino acid
residues incredibly difficult. However, due to the evolutionary conservation of the core
histones, and because the budding yeast genome encodes only two copies of canonical
H3 and H4, S. cerevisiae has become an essential model organism for conducting cuttingedge, mechanism-based experiments that are highly translatable. Indeed, our current
knowledge of functional genomics, histone dynamics and epigenetic modifications was
built on work conducted in budding yeast [23].
Coordination of Nutrient Availability, Anabolism and Cellular Aging
It is critical for all eukaryotic organisms to be able to rapidly adjust their growth
and proliferative profiles to account for changing extracellular conditions or intracellular
deficits. This principle is most critical as it relates to active cell division, as an inability to
coordinate mitosis with nutrient and energy states may prevent sufficient biomass
accumulation and have adverse downstream consequences on cell viability [24-27]. In
response to these pressures, cells have developed highly conserved nutrient sensing
complexes, such as the target of rapamycin complex 1 (TORC1), which couples
extracellular nutrient signals with the appropriate intracellular response [28]. Aberrant
flux through these sensing pathways contributes to a number of age-related diseases,
including diabetes, cancer and cardiovascular disease [29].
Identification of the Target of Rapamycin Genes
The discovery of target of rapamycin (Tor), a protein kinase responsible for
mediating cell growth and proliferation in coordination with growth factors and
environmental nutrient status, can be traced back to the isolation of rapamycin, a
macrolide produced by the Easter Island soil bacterium Streptomyces hygroscopicus [30].
Though once a promising antifungal compound, rapamycin’s adverse effects on host Tcell proliferation has led to its present day use as an immunosuppressant and anti-cancer
agent (as reviewed by Benjamin)[31]. The rapamycin-dependent effects on T-cell
proliferation require the FK506-binding protein (FKBP), a binding partner now known to
bridge the association of rapamycin and the FKBP-rapamycin binding domain of Tor [3234].
The proliferation defect first identified in rapamycin treated T-cells is also
observed in the budding yeast Saccharomyces cerevisiae, and in both instances,
deficiencies are attributable to an early G1 cell-cycle arrest [35]. Genome sequencing of
spontaneously rapamycin resistant yeast mutants identified the two genes responsible for
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mediating the rapamycin phenotype, and they were aptly named target of rapamycin 1
and 2 (TOR1 and TOR2) [35]. These genes encode a unique pair of PI3-like
serine/threonine kinases. Subsequently, an orthologous kinase was discovered in higher
order organisms, termed mechanistic TOR (mTor), and since then, Tor kinases have been
reported to be conserved across all eukaryotes [36-38]. Characterization of Tor kinase
substrates has proven difficult due to the lack of a true consensus sequence, though a few
are known and will be discussed below. For clarity and simplicity, nomenclature for the
yeast Tor pathway will be used from herein unless otherwise noted.
The TORC1 Complex
The Tor kinases are incorporated into one of two signaling complexes: target of
rapamycin complex 1 or 2 (TORC1/2) [39-41]. In metazoans, these complexes are known
as mechanistic TORC1/2 (mTORC1/2). There are considerable structural and functional
differences between TORC1 and TORC2, the most relevant being that TORC1 is
sensitive to environmental stimuli and rapamycin-dependent inhibition while TORC2 is
not. Because the overarching interest of our lab is in environmentally regulated
epigenetic processes, TORC1 will be our focus for the remainder of this work.
TORC1 consists of the Tor1/2 kinase, Lst8, Kog1, and Tco89 [42]. Lst8 and the
Tor2 kinase can be found in both TORC1 and TORC2, but Tor1, Kog1 and Tco89 appear
to be TORC1-specific [43]. Accordingly, temperature sensitive mutants of Kog1
(essential), or tco89Δ mutants (non-essential), sensitize cells to direct TORC1 inhibition
[43, 44]. Electron microscopy studies have characterized the association between the Cterminal WD40 domain of Kog1 and the N-terminal HEAT repeats of the Tor kinases
[45]. Kog1 and its mammalian ortholog, Raptor, contribute to TORC1 function by
facilitating a series of interactions, including between the kinase and its substrates [46,
47], and between TORC1 and the vacuole (discussed in detail below) [48, 49]. Further,
when nutrients are limiting, the Rho1 GTPase associates with Kog1, resulting in
inhibition of TORC1 [50]. Recently, it was reported that TORC1-bound Kog1 is more
stable than free Kog1, suggesting association with the complex may also serve to
stabilize Kog1 [51].
By comparison, little is known about Tco89. It is currently believed to be a yeastspecific component of TORC1, and homologs have been identified in S. pombe and C.
albicans [52, 53]. The existence of a mammalian Tco89 seems likely however, given the
considerable conservation of the TORC1 axis. tco89Δ cells have abnormal cellular
physiology and budding patterns, as well as dramatically increased sensitivity to stress;
including heat, caffeine, MMS, rapamycin and salt [52, 54-60]. tco89Δ mutants
phenotypically resemble vacuole mutants (ego1Δ, ego3Δ, gtr1Δ and gtr2Δ), as these
strains are all acutely sensitive to rapamycin and unable to reengage the cell cycle
following TORC1 stress [43, 61] (discussed in detail later). In support of the above,
Tco89 has been reported to mediate physical interactions between TORC1 and the
vacuole [49]. Tco89 has also been shown to directly associate with Vac8, an armadillo
repeat protein which affects vacuolar functions and caffeine resistance [62], and fructose-
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1,6-bisphosphate to mediate its vacuolar turnover [63]. Still, the majority of studies that
mention tco89Δ do so in the context of suppressor screens [64, 65]. Most of these screens
also identify tor1Δ, suggesting that Tco89’s most prominent function involves
maintaining TORC1 activity. Interestingly, our group has shown that TORC1-dependent
histone acetylation is responsive to tco89Δ but not tor1Δ [66]. A mammalian ortholog of
Tco89 could be an attractive therapeutic target given the dramatic and permanent cell
cycle arrest that occurs in its absence when sub-inhibitory doses of rapamycin are
administered [43, 49].
Downstream Effectors of TORC1
When nutrient status and environmental conditions are favorable, TORC1 actively
promotes growth programs and simultaneously suppresses stress responses through
coordination of a downstream kinase (Sch9) and a series of Tap42-associated
phosphatases (Figure 1-4). Conversely, diminished TORC1 signaling during times of
starvation or rapamycin treatment causes cells to enter a quiescent state where anabolic
flux is suppressed. Fascinatingly, long-term TORC1 inhibition, and subsequent
suppression of anabolism, has been shown to extend lifespan across a number of model
systems [67-74]. These rapid and dramatic changes in intracellular processes require a
coordinated shift in gene expression, which TORC1 has been shown to regulate at the
level of mRNA transcription (via transcription factor localization [75]) and translation (at
the initiation step of elongation [76-78]). But how TORC1 regulates gene expression,
particularly as it relates to chromatin structure, remains a poorly defined function of the
pathway.
Recently, it was demonstrated that TORC1 also signals through the Ypk3 kinase
to promote phosphorylation of the ribosomal proteins Rps6a/b, though the mechanism
remains unclear [79]. Phosphorylation of S6 serves as a readout for TORC1 activity in
eukaryotic cells [80], and it will be used as such in the studies presented herein. For now
though, we will focus on the Sch9 kinase and the Tap42 phosphatases as they are the
best-characterized effector molecules downstream of yeast TORC1 (Figure 1-4).
Sch9 kinase
Sch9 is an AGC protein kinase whose activity is directly promoted by TORC1dependent phosphorylation [80]. The degree of control TORC1 exerts on Sch9 is evident
in the fact that sch9Δ cells phenocopy the effects of caloric restriction (CR), including
extended lifespan, and behave very similarly to a tor1Δ [71, 72, 80, 81]. It is important to
note that there is also evidence that Sch9 and TORC1 may function synergistically, rather
than redundantly, in sensing environmental stressors [82]. This concept is supported by
the fact that phosphorylation of the Sch9 activation loop may occur independently of
TORC1 via the Pkh1/2 kinases, possibly tying Sch9 into sphingolipid homeostasis as
well as to classical TORC1 stimuli [83-85]. In the case described above, an additional
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Figure 1-4. Downstream effectors of the TORC1 signaling pathway and their
functions in S. cerevisiae.
TORC1 effectors include yeast protein kinase 3 (Ypk3), the Sch9 kinase, and the Tap42associated phosphatases. Cellular processes mediated by each are presented as well. See
text for more details.
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TORC1-dependent phosphorylation mark on the hydrophobic motif of Sch9 is able to
fine-tune the Pkh1/2-initiated activity.
The basic function of Sch9 is to promote proper cell cycle progression,
transcription initiation, and translation, while simultaneously suppressing induction of
autophagy [80, 86-88]. Under favorable environmental conditions, Sch9 phosphorylates
and inhibits the transcriptional repressors Maf1, Dot6, Tod6 and Stb3, ensuring
transcription of genes necessary for ribosomal biogenesis [60, 86, 89]. Sch9 activity also
feeds into the suppression of autophagy, seemingly in concert with RAS/PKA, via
regulation of the Atg1-Atg13-Atg17 kinase complex [88]. Additionally, to promote cell
cycle progression, Sch9 targets the ubiquitin conjugating enzyme, Cdc34 [90]. An
interesting study from Weisman et al. also ties Sch9 into cell cycle control through a
unique vacuolar inheritance mechanism. They demonstrate that if this inheritance fails,
the cell cycle arrests at G1 in an Sch9-dependent fashion [91]. Conversely, inhibition of
Sch9 during times leads to Gcn2-mediated phosphorylation of the translation factor
eIF2a, which inhibits its function and blocks protein synthesis [82]. It was also suggested
recently that Sch9 regulation of Maf1 may contribute to CR-induced lifespan extension
[92].
The PP6 phosphatase complex and Tap42
The Tap42-associated phosphatases are a family of functionally distinct, modular
protein phosphatase complexes, which include PP2A, PP4, PP6 and PPG1 [93-96]. These
complexes are best known as regulators of non-preferred nitrogen catabolism and the
stress response. For brevity, and because PP6 will be the major focus of our work, it will
be the only complex discussed in-depth.
The PP6 phosphatase complex exists as a heterodimer consisting of the ceramideresponsive catalytic subunit, Sit4, and one of four Sit4-associated regulatory proteins
(Sap4, Sap155, Sap185, or Sap190) [97]. Sit4 regulates expression of the cyclin genes
and is required for the execution of cell cycle START (G1), bud formation, initiation of
DNA synthesis, and spindle pole body duplication [98, 99]. Overexpression of the Saps
in a temperature sensitive Sit4 mutant can partially reverse the observed growth defects,
while a complete ablation of the Saps in an otherwise wild-type cell induces a sit4Δ-like
slow growth phenotype and G1 delay [97]. Association of the catalytic and regulatory
subunits appears to be cell-cycle dependent and indispensable for Sit4 activity in vivo.
And while some speculate that the Saps regulate PP6 substrate specificity, their exact
function is currently unknown. There is evidence which suggests that each Sap has a
unique and distinct contribution to PP6 function, but there is also data that demonstrates
at least moderate functional redundancy exists as well [97, 100, 101]. Interestingly,
overexpression of metazoan PP6 regulatory subunits (PP6R2 and PP6R3) in the absence
of the Saps restores growth and reverses rapamycin sensitivity, suggesting rather
significant evolutionary conservation of this modular phosphatase complex [102].
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Sit4 is highly influential in the cellular response to altered nutrient states,
particularly to changes in amino acid availability. During starvation, the Gln3, Gat1, and
Nil1 transcription factors are dephosphorylated by Sit4, which triggers dissociation from
their cytoplasmic anchors and entry into the nucleus [103]. There, these factors drive high
level expression of genes encoding permeases and enzymes needed to transport and
utilize poor nitrogen sources. At the same time, the Sit4 phosphatase is also known to
target the Npr1 kinase, leading to its activation and the subsequent stabilization of the
general amino acid permease Gap1 [104]. These effects are known collectively as the
Nitrogen Catabolite Repression (NCR) response.
Tap42’s association with its family of phosphatases has a somewhat muddled
history. It was initially identified in yeast as a 42kDa protein that specifically associates
with the PP2A and PP6 protein phosphatase complexes [105]. Tap42 is now known to
associate with all of the other PP2A-like phosphatase complexes, including the
aforementioned PPG1 and PP4 [96]. Somewhat surprisingly, there is far less Tap42 in the
cell than there are phosphatases, as only about 5-10% of cellular PP2A-like phosphatases
are bound to Tap42 [105]. Such stoichiometry could suggest that these phosphatases
possess Tap42-independent functions or possibly additional substrates that have yet to be
identified. Chen et al. utilized a yeast two-hybrid screen to identify a mammalian protein
they dubbed α4, which is also capable of binding the N-terminal portion of these
phosphatase complexes [106]. The authors report significant sequence conservation
between α4 and Tap42, suggesting the proteins may be homologs.
In the late 1990’s, evidence began accumulating that Tap42 and α4 act as negative
regulators of the PP2A-like phosphatases. First, Nanahoshi’s group reported that PP2Adependent dephosphorylation of eIF-4E binding protein was inhibited by the presence of
Tap42 and α4 [107]. Subsequently, Beck and Hall suggested that Tap42 and Sit4 form a
complex following Tap42 phosphorylation by TOR, and postulated that this was the
inactive form of the phosphatase [75]. They found that when phosphatases were
dissociated from Tap42, this was accompanied by a dephosphorylation of many
downstream targets, concluding that phosphatase release led to its activation. This idea
was supported by Jiang and Broach, who later demonstrated that Tap42 association to
Sit4 is indeed rapamycin responsive and dependent on TORC1 phosphorylation of Tap42
[108]. Gene expression profiling identified dynamic expression level changes that mirror
the release and disassembly of the Tap42-Sit4 complex [109]. Similarly, the inactivation
of Tap42 was shown to severely attenuate the rapamycin-induced expression of genes
under control of the Sit4-regulated Gln3 transcription factor [110].
More recently, however, many of the initial claims made about Tap42’s function
as a negative regulator, as well as its identity as a homolog to α4, have been questioned.
In 2006, it was reported that rather than Tap42 functioning as a negative regulator, it may
actually be a positive effector of the phosphatases [111]. The timing of this paradigmshifting experiment proved to be key as it utilized shorter, more closely spaced time
points than the Hall study [75]. The authors demonstrated by fractionation that Tap42phosphatase complexes exist primarily on membrane structures through association with
TORC1. They also showed that the TORC1-associated population of Tap42 is almost
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exclusively phosphorylated, while the cytoplasmic pool is not. Importantly, they reported
that the TORC1-Tap42-Sit4 association is environmentally sensitive, as rapamycin
treatment or nutrient starvation releases the Tap42-phosphatase complex into the cytosol.
The cytosolic complex then dissociates further, leaving Tap42 and the free phosphatase.
Finally, the authors demonstrated that Tap42 dephosphorylation and complex
dissociation occurs long after phosphatase activation. These results ultimately illustrated
that the cytoplasmic Tap42-PP6 phosphatase complex is indeed the active form, and
that the dissociation of Tap42 from Sit4 is not the trigger for phosphatase activity as
was previously believed. Interestingly, the interaction between Tap42 and PP6 is
independent of whether the Saps are present [105].
This conclusion has subsequently been supported by other groups that have
demonstrated that phosphatase activity, and particularly Sit4 function, depends on the
presence of Tap42 [96]. In fact, loss of Tap42 prevents Sit4-dependent stress-response
genes from being activated [110]. It has also been reported that overexpression of Tap42
along with these phosphatases leads to a growth inhibition phenotype that is more
substantial than is seen with the phosphatases alone [105]. Altogether, these results show
that Tap42 is indispensable for PP6 phosphatase activity, and we speculate that like α4
[112], Tap42 may be functioning as a chaperone to protect the integrity of the
phosphatase complexes.
To summarize, when conditions are favorable for growth, phosphatases are
sequestered at the vacuole due to TORC1 phosphorylation of both Tip41, a cytoplasmic
binding partner of Tap42, and Tap42 itself (Figure 1-5A). During the initial stages of
nutrient stress (Figure 1-5B), the Rho1 GTPase competitively inhibits the Tap42-Kog1
association at the vacuole, which releases and activates the Tap42-PP6 phosphatase
complex [50]. Sit4-dependent dephosphorylation of the stress responsive transcription
factors results in their localization to the nucleus, and a corresponding shift in the gene
expression patterns of the cell. Later in the starvation response (Figure 1-5C), the
TORC1-dependent phosphorylation marks on Tip41 and Tap42 are removed, although
the responsible phosphatase remains unclear (some postulate it may actually by a selfregulatory function of Sit4). At this point, Tip41 competes for the binding of Tap42 and
promotes Tap42-Sit4-Sap complex disassembly [113]. This inactivating event usually
occurs approximately 30 minutes after initial introduction of the stress, though it is
unclear whether Sit4 remains associated with the Sap following release from Tap42
(denoted by question mark in Figure 1-5C). Eventually, when the environment permits,
an inactive holocomplex of Tap42-Sit4-Sap is reformed at the vacuolar surface through
associations with active TORC1. As was mentioned above, only a small amount of the
Sit4 in a cell is bound to Tap42, and this is almost exclusively the TOR-responsive
fraction. What the remainder of Sit4 is doing in the cell, and how phosphatase molecules
are “selected” by Tap42, remains to be seen.
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Figure 1-5. The activation of Tap42-associated phosphatases in response to
TORC1 inhibition.
Cartoon schematic describing the sequence of events culminating in Tap42-associated
phosphatase activation as a cell transitions from a nutrient complete environment (A) to
an amino acid deficient one (B and C). Active signaling molecules are indicated in green
while inactive complexes are shown in red. The question mark in (C) denotes a point
which requires future study. See text for more information.
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Amino Acid Signaling through TORC1
In order to sense environmental quality, one of the upstream nutrients TORC1 is
particularly sensitive to is nitrogen, typically in the form of free amino acids. The quality
of a nitrogen source is defined by its ability to promote glutamine accumulation. These
catabolites must fuel the equilibrium reactions which maintain cellular levels of αketoglutarate, ammonia, glutamine and glutamate. The mechanism through which
TORC1 responds to fluctuations in nitrogen donor quality and amino acid availability is
only now being delineated, and yet there is already a striking level of similarity between
yeast and mammals, as described below.
Yeast
In yeast, the major amino acid sensing node is the EGO complex, consisting of
the structural subunit Ego1, the newly discovered Ego2, a homodimer of Ego3, and the
Rag GTPases Gtr1 and Gtr2 [61, 114, 115]. The active conformation of the Rag GTPases
includes GTP-bound Gtr1 and GDP-bound Gtr2. When amino acids are not limiting, the
guanine nucleotide exchange factor (GEF) activity of Vam6 is activated, which
subsequently inhibits the Gtr1-targeted GTPase activating protein (GAP) function of the
SEACIT complex [49, 116]. Concurrently, activity of the recently discovered Gtr2 GAP,
Lst4-Lst7, is promoted and when combined with the effects of SEACIT inhibition, results
in the active Gtr1(GTP)-Gtr2(GDP) configuration [117]. This stabilizes the association
between EGO and the TORC1 subunits Kog1 and Tco89, leading to activation of the
TORC1 complex [49, 61, 114, 118].
Mammals
The lysosome is the critical amino acid sensing organelle in mammals, and
functionally, it is quite similar to the yeast vacuole. The Ragulator complex resides on the
lysosomal surface and is analogous to the EGO complex found in yeast. Ragulator
consists of a scaffolding subunit p18 (LAMTOR1, analogous to Ego1), a heterodimer of
p14 and MP1 (LAMTOR2 and LAMTOR3, analogous to Ego3), and a heterodimer of
C7orf59 and HBXIP (LAMTOR4 and LAMTOR5, suggested analogy to EGO2) [119123]. Additionally, Ragulator is associated with a heterologous pair of Rag GTPases,
RagA/B and RagC/D. Regulation of these GTPases occurs in response to nucleotide
loading, very similar to how Gtr1 and Gtr2 function in yeast. Specifically, when amino
acids levels are sufficient, Ragulator’s intrinsic RagA/B GEF activity is stimulated by the
v-ATPase, the RagA/B GAP activity of GATOR1 is diminished, and the RagC/D GAP
activity of FLCN-FNIP1/2 is activated [123-126]. These events coordinate the active
nucleotide configuration of the Rag GTPases, with GTP-bound RagA/B and GDP-bound
RagC/D [127]. In their active conformation, the Rag GTPases function to bridge
mTORC1 and the lysosome [128]. At the lysosomal surface, mTORC1 is activated via
interactions with the Rheb1 GTPase [129]. A recent study from Fawal et al. suggests that
in addition to amino acid dependent spatial regulation of mTORC1, there may be a
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mechanism in place which also links amino acid availability and the cellular distribution
of Rheb1 [130]. The group identified microspherule protein 1 (MCRS1) as a critical
mediator of Rheb lysosomal localization and nucleotide loading status in an amino aciddependent fashion. Until recently, it was unclear how cells relayed amino acid levels in
the lysosomal lumen to the Ragulator complex and mTORC1. A number of groups now
report that the transmembrane solute carrier SLC38A9 is able to monitor amino acid
accumulation in the lysosomal lumen and interact with the Ragulator complex in an
amino acid-dependent fashion [131-133]. In total, activation of mTORC1 requires
significant spatial and temporal coordination, as the Rags are responsible for promoting
mTORC1’s localization to the lysosome, MCRS1 is responsible for bringing active Rheb
to the lysosome, and Rheb is responsible for activation of mTORC1 [128].
The oncoprotein Rab1A was also recently identified as an amino acid responsive
activator of mTORC1, but interestingly, it does so independently of the Rag GTPases
[134]. Rab1A is overexpressed in colorectal cancer and this correlates with tumor
invasiveness and an overall poor prognosis. High levels of Rab1A means cells are far
more sensitive to amino acid starvation. In fact, they require high levels to continue
growing and are said to be nitrogen “addicted”. Altogether, this suggests that
deregulation of amino acid signaling through mTORC1 can contribute to cellular
dysfunction and organismal disease.
TORC1’s Nuclear Functions
Given the array of environmental stimuli that influence TORC1 activity, and the
role TORC1 plays in regulating the cell cycle, gene expression and anabolism, the
complex is uniquely qualified to serve as a link between nuclear processes and nutrient
availability. Yet to date, most of what is known about TORC1 is in reference to its
cytoplasmic functions. This is due in large part to a number of publications in both yeast
and mammalian cell culture models that suggest the majority of TORC1 resides in the
cytoplasm, and more specifically, at the vacuole/lysosomal compartments [119, 124, 128,
135]. And while this view represents the historical understanding of TORC1, it fails to
account for an emerging body of literature which has identified a role for nuclearlocalized Tor kinase, and even components of TORC1, in transcriptional regulation [136139]. There is still a considerable amount of research to be done in order to fully
understand the nuclear functions of Tor kinases. However, the fact that TORC1 can be
found in the nucleus, and even at specific gene promoters, means that the complex may
directly bridge environmental status to cell cycle regulation, gene transcription, and/or
the epigenome.
Effects on ribosomal DNA transcription
Traditionally, there have been two levels at which TORC1 can affect
transcription, particularly as it relates to ribosome biogenesis. The first involves
regulation of RNA polymerase I (RNAPI) promoter binding through phosphorylation of
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Rrn3 (TIF-IA in mammals); an integral transcription factor which localizes to the rDNA
to recruit RNAPI. At the rDNA, RNAPI is responsible for production of the 35S preribosomal RNA (rRNA), which is ultimately co-transcriptionally processed into the 25S,
18S, and 5.8S rRNAs. These rRNAs are critical components of the ribosome machinery.
Inhibition of TORC1 results in a rapid redistribution of RNAPI from the nucleus to the
nucleoplasm, as well as enhanced Rpd3 binding to the rDNA [140, 141]. Subsequent
Rpd3-dependent histone H4 lysine 5 and 12 deacetylation promotes condensin complex
association, which compacts and stabilizes chromatin leading to decreased nucleolar
volume [140, 142]. There is controversy in the field as to whether the RNAPI
redistribution is a consequence of Rpd3-dependent transcriptional repression (via
deacetylation), or is independent of Rpd3 [140, 143]. TORC1 has also been identified as
a regulator of RNAPII-dependent RP gene expression, and RNAPIII-dependent 5S rRNA
and tRNA production. It does so via Sch9-dependent phosphorylation of RP transcription
factors such as Rtg1/3, Gln3, Tod6 and Dot6, or the RNAPIII negative regulator Maf1
[75, 86, 144-149]. These phosphorylation events mediate both the activity and
localization of these factors as was mentioned in the previous sections.
TORC1, sirtuins, and the epigenetic modification of histones
Besides the direct mediation of polymerase function and transcription factor
localization, there seems to be a poorly characterized third layer of TORC1-dependent
effects on gene expression that involves regulation of chromatin structure through histone
post-translational modifications [12, 66, 150-152]. Work from our lab shows that direct
inhibition of yeast TORC1, either through subunit deletion or rapamycin treatment,
results in globally diminished histone H3 lysine K56 acetylation (H3K56ac); a mark tied
to DNA repair, maintenance of rDNA copy number, and overall genomic stability [66,
153, 154]. We also demonstrate that TORC1-regulated H3K56ac influences RNAPI
binding to the 35S rDNA, as well as binding of the key Pol I transcriptional regulators
Hmo1 and the SSU processome [66]. Although the exact mechanism linking TORC1 to
this acetyl mark is currently unknown, our previous data suggests that regulation of the
sirtuin histone deacetylases may be involved. Specifically, deletion of HST3 or HST4 is
sufficient to restore H3K56ac in a TORC1 mutant [66].
The sirtuins are a conserved, NAD+-dependent family of histone deacetylases that
in yeast includes Hst1, Hst2, Hst3, Hst4 and Sir2 (summarized in Table 1-1). They are
sometimes referred to as class III histone deacetylases. Interestingly, despite their varied
functions, all seven human sirtuins (SIRT1-7) most closely resemble yeast Sir2 according
to standard BLAST alignment [155]. The relationship between sirtuins and TORC1 is
particularly interesting as both have been heavily discussed as regulators of aging [70, 81,
156]. As mentioned previously, inhibition of TORC1 with rapamycin or CR extends
lifespan and, fascinatingly, activation of sirtuin function with resveratrol mimics these
effects [70, 157-159]. As a whole, the sirtuins’ best characterized role in the cell is
transcriptional silencing, particularly at the silent mating type loci, telomeres and rDNA.
To date, there are only a few characterized substrates for the yeast sirtuins, including the
non-histone protein Ifh1 (deacetylated by Hst1 and Sir2), and the histone residues
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Table 1-1.
Summary of sirtuin histone deacetylase localization and substrate
specificity in yeast.
HDAC
Hst1

Hst2

Hst3

Subcellular
Localization
Primarily
Nuclear [160]

Genomic
Localization
Telomeric repeats,
tRNA genes,
Pol-II transcribed
genes [161]

Histone
Substrates
H3K4Ac [162]

Primarily
Cytoplasmic
(shuttled out
of nucleus [160,
164, 165]
)

Telomeric repeats,
rDNA, Silent mating
type loci, Stationary
phase granules [165-

H4K16Ac [168]

Telomeric repeats,
rDNA, Silent
chromatin,
Sites of DNA repair

H3K56Ac [154, 174,

Primarily
Nuclear
(shuttles to
mitochondria
[160, 176]
)

Telomeric repeats,
rDNA, Silent
chromatin,
Sites of DNA repair

H3K56Ac [154, 174,

Primarily
Nuclear [160]

Telomeric repeats,
rDNA, Silent mating
type loci [13, 161, 172,

H3K4Ac [162]
H3K9Ac [177],
H4K16Ac [177, 178]

Primarily
Nuclear [160]

Non-Histone
Substrates
Ifh1 [163]

167]

175]

[153, 169-173]

Hst4

Sir2

175]

[153, 169-173]

173]
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Ifh1 [163]

H3K4ac (deacetylated by Hst1 and Sir2), H3K9ac (deacetylated by Sir2), H3K56ac
(deacetylated by Hst3 and Hst4), and H4K16ac (deacetylated by Hst2 and Sir2) [154,
162, 163, 168, 170, 174, 175, 177, 178]. The sirtuins are primarily found in the nucleus,
with two exceptions; Hst2 is actively shuttled from the nucleus to the cytoplasm in a
Crm1-dependent fashion due to the presence of a nuclear export signal [164], while Hst4
is known to move from the cytoplasm to the mitochondria in response to biotin starvation
[176]. A similar shuttling phenomena is also seen with the mammalian sirtuins, SIRT1
and SIRT2 (see Table 1-2).
Hst3 and Hst4 are unique in that they appear to be regulated in a cell-cycle
dependent fashion. The protein levels of Hst3 fluctuate throughout the cell-cycle in
response to Mec1- or Cdk1-dependent phosphorylation, which promotes SCFCdc4dependent polyubiquitination and degradation via the proteasome [179, 180]. A highthroughput screen designed to identify phosphoproteins that bind the SCFCdc4 ubiquitin
ligase determined that Hst4 may be regulated in a similar fashion [181]. Importantly, the
phosphatase that opposes these SCFCdc4 binding phosphomarks is still unknown.
Of all the sirtuins, the best characterized is Sir2. Its role in cellular aging and CRmediated lifespan extension has been investigated over the last decade, with many groups
linking deletion of SIR2 to rDNA instability and yeast senescence [13, 69, 182, 183].
Specifically, inhibition of yeast TORC1 promotes rDNA association of Sir2, possibly in
concert with the RENT complex, ultimately resulting in a hypoacetylated and deactivated
rDNA chromatin architecture [13]. Sir2-dependent rDNA deacetylation enhances
stability, suppresses extra-ribosomal circle formation, and significantly extends yeast
replicative lifespan [13].
There are also noted interactions between mTORC1 and sirtuins in mammals. For
example, SIRT4 gene expression is tied directly into glutamine metabolism via mTORC1
[184]. When amino acids are limiting, mTORC1 promotes proteasomal destruction of
CREB2, a transcriptional regulator of SIRT4, which ultimately results in a decrease in
SIRT4 levels. In this way, mTORC1 can modulate activation of the glutamine
dehydrogenase promoter, a critical regulatory step in the production of key TCA cycle
metabolites. There are a number of cancers that display aberrant SIRT4 expression,
suggesting that dysfunctional mTORC1 activity may promote transformation through
altered cell metabolism at the level of chromatin regulation. A second mammalian sirtuin,
SIRT1, has been identified as a negative regulator of mTORC1 via interactions with the
upstream TSC complex [185]. Interestingly, SIRT1 overexpression can complement loss
of Sir2 at the level of rDNA stabilization, and SIRT6 (like Hst3 and Hst4) deacetylates
H3K56ac, suggesting there is evolutionary conservation of function of these enzymes
[177, 186].
A number of fascinating genetic interactions between TORC1 and histone H3
suggest signaling through the TORC1 pathway, or TORC1-mediated epigenetic
modifications, may directly influence other chromatin-based processes. Our laboratory
screened individual mutants of the majority of residues on the H3 and H4 tails and found
only one, H3K37, whose maintenance is indispensable in response to decreased TORC1
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Table 1-2.
mammals.

Summary of sirtuin histone deacetylase localization and specificity in

HDAC Subcellular Localization

Histone
Substrates
H3K9Ac [177],
H4K16Ac [177, 189,
190]
, H3K9me2 [191]
(indirect)

SIRT1

Actively shuttles between
nucleus and cytoplasm,
primarily nuclear [187, 188]

SIRT2

Actively shuttles between
H4K16Ac [168]
nucleus and cytoplasm,
primarily cytoplasmic except
during G2-M [187, 214, 215]

SIRT3

Mitochondrial,
small nuclear fraction at
stress response genes [187, 219-

H4K16Ac [222]
(indirect)

221]

Non-Histone
Substrates
LC3 [192, 193], Atg5/7/8
[194]
, p300 [195], MOF
[196]
, Tip60 [197, 198], p53
[199-201]
, FOXO factors
[202, 203]
, NFκB [204], cMyc [205], HIF-1α [206208]
,
PGC-1α [209],
LKB1 [210], Ku70 [211],
PARP1 [212, 213]
p53 [216], FOXO3a [217,
218]

AceCS2 [223, 224],
ALDH2 [225],
SdhA [226, 227], Ku70 [228]

SIRT4

Mitochondrial [187, 221, 229]

GDH [230]

SIRT5

Mitochondrial [187, 221]

CPS1 [231, 232]

SIRT6

Nuclear [187, 233]

H3K9Ac [234-236],
H3K18Ac [237],
H3K56Ac [236]

SIRT7

Nucleolar [187, 239]

H3K18Ac [240]
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CtIP [238]

activity [152]. These dramatic phenotypes are independent of glucose-dependent
Ras/PKA signaling, suggesting the linkage between TORC1 and H3K37 is specific.
Interestingly, because TORC1 is also sensitive to glucose, this may indicate that H3K37
is more strongly coupled to the amino acid sensing arm of TORC1. Mutation of this
lysine to an alanine (H3K37A) results in a dramatic redistribution of high mobility group
proteins (HMGs), including Nhp10, from chromatin to the cytoplasm accompanied by
accelerated chronological aging. This is particularly fascinating considering that Nhp10 is
a member of the INO80 chromatin remodeler, and TORC1 has already been shown to
affect transcription through altered recruitment of histone chaperones and chromatin
modifying complexes [241, 242]. A number of other remodelers are also anchored to
chromatin through their HMG-containing subunit, a family of structural proteins that will
be discussed further below.
High-Mobility Group Proteins: “The Architectural Transcription Factors”
HMGs are highly charged, extremely abundant, and the second most common
protein found on chromatin besides the histones. There are three families of HMGs in
mammals: HMGA, HMGB and HMGN. All three compete with H1 for binding to the
linker DNA, and weakening of this H1 association results in decreased chromatin
compaction [243-245]. Because yeast do not have obvious HMGA and HMGN factors,
the HMGB class will be our main focus. HMGB family members bind the minor groove
of B-form DNA with relatively low sequence specificity to introduce sharp bends or
kinks into the strand. They are particularly enriched at the nucleosomes flanking
transcriptional start sites, but can also be found at four way DNA junctions and
significantly under twisted DNA [246]. The effect HMGBs have on gene expression
(stimulatory or inhibitory) is often context dependent. Some data suggest the HMGBs
simply distort DNA to promote incorporation of the transcriptional machinery, while
others argue that in addition to bending DNA, HMGBs may also bridge associations of
basal transcription factors (ex. TBP) with the transcriptional machinery [247-250].
The best-characterized mammalian HMGB member is the prototypical HMGB1.
It has been identified as the most mobile of all nuclear proteins, as it can traverse the
entire nuclear compartment in just over a second [251]. Interestingly, during cellular
apoptosis, HMGB1 movement in the nucleus ceases and it remains anchored to
chromatin, though the mechanism regulating this process is unknown [251]. This effect is
believed to promote severely under-acetylated heterochromatic DNA. In vitro
nucleosome binding studies, conducted with an array of HMGB1 truncation mutants,
identified a specific C-terminal acidic sequence of HMGB1 that is necessary to promote
transcription [252]. Crosslinking experiments show that the acidic region functions to
enable HMGB1 to associate with the nucleosome via the histone tails, and specifically
H3. Kawase et al. followed up on this work, utilizing mass spectrometry to perform a
characterization of the association between HMGB1 and the nucleosome [253]. They
reported that the acidic C-terminal tail of HMGB1 makes direct contact with H3K36 and
H3K37 on H3, suggesting these sites play a vital role in securing HMGB1 to chromatin.
HMGB1 is released from chromatin during necrosis to promote the innate immune
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response by binding the Toll-like and RAGE receptors on immune cells [251, 254].
Association of HMGB1 with its RAGE receptor in tumor cell mitochondria is essential
for optimal mitochondrial function, enhanced ATP production, and the dysfunctional
bioenergetics observed in tumor microenvironments [255]. The nuclear to cytoplasmic
translocation, and subsequent extracellular secretion, of HMGB proteins in senescent
cells also promotes the senescence-associated secretory phenotype (SASP), which
increases cancer risk in aging tissues [256]. Considering all of the evidence described
above, deregulation of HMGB chromatin binding in mammals, particularly as cells age,
has the potential to be transformative.
Yeast HMGBs fall into two general categories based on the number and structure
of their HMG domains: a single sequence-specific HMG box, or two relatively sequenceindependent HMG boxes. There are seven known HMGBs in yeast, Hmo1, Nhp6a/b,
Nhp10, Ixr1 [257-259], Rox1 [258, 260-262] and Abf2 [263-266]. We will elaborate on
the function of the HMGs that are particularly relevant to this work; Hmo1, Nhp6a/b and
Nhp10.
Hmo1 is probably the best-characterized member of the yeast HMGB family.
Hmo1 is exclusively nuclear and organized into three domains, including a classical
HMG box required for DNA binding and bending (“HMG Box B”), a non-traditional
HMG box whose function is controversial (“HMG Box A”), and a lysine-rich C-terminal
nucleolar targeting sequence that also contributes to DNA binding and bending [267,
268]. The HMG boxes can interact with one and other, and HMG box A is also able to
associate with Hmo1’s C-terminal tail. Hmo1 chromatin binding promotes compaction,
the introduction of DNA loops or bends, and SWI/SNF- and ISWIa-dependent chromatin
remodeling [267, 269, 270]. Hmo1 is involved heavily in ribosome biogenesis, an
anabolic process significantly regulated by TORC1 (discussed previously). It is highly
enriched in the nucleolus (nucleolar/nucleoplasmic interface) on active rDNA, and also
localizes to the promoter of the RP genes [66, 271-274]. An elegant complementation
study by Albert et al. identified Hmo1 as an rDNA binding component of yeast Pol I
[275]. The authors also demonstrated that Hmo1 has a robust genetic interaction with
Rpa49, suggesting involvement in Pol I initiation.
Nhp6a and Nhp6b are functionally redundant HMG family members, although
Nhp6a is expressed at much higher levels in the cell. They are homologous to
mammalian HMGB1/2, and play a significant role in chromatin remodeling [276, 277].
Nhp6a contributes to the recruitment of the FACT histone chaperone complex, which
promotes a chromatin state permissive for transcription, replication, and repair [278-281].
Nhp6a also enhances the nucleosome sliding ability of the SWI/SNF ATP-dependent
chromatin-remodeling complex [269]. In vivo studies with Nhp6a find that even in the
absence of its acidic domain, chromatin context is still a key determinant of genome-wide
binding [279, 282]. Given these interactions with well-characterized mediators of
chromatin structure, aberrant Nhp6a/b localization or abundance is certain to impact gene
expression patterns and overall cellular function. And finally, similar to the mammalian
HMGB1 [251, 254], the nuclear to cytoplasmic translocation of Nhp6A is a hallmark of
necrosis suggested to occur as a consequence of chronological aging [283].
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Nhp10 is somewhat unique as it is the only HMGB known to associate with the
INO80 ATP-dependent chromatin remodeling complex [284]. Nhp10 functions in INO80
to bridge the remodeler’s interaction with phosphoH2A.Z at double strand breaks, and
also to protect DNA ends from exonucleatic cleavage at the break site [284-287].
Sekiguchi et al. find that in strains where INO80’s catalytic subunit has been mutated,
loss of EGO function is synthetically lethal, implicating INO80 in TORC1-dependent
chromatin regulation [288]. As described above, Nhp10 chromatin binding also appears
to be linked with TORC1 activity via the H3K37 residue, though the exact nature of this
relationship is currently unclear [152].
Tor Dysfunction and Age-Related Pathologies
Aging is a very complex process which remains poorly understood at the
molecular, cellular, and organismal level. Studies over the past several decades have
identified significant overlap between lifestyle, environmental factors, and epigenetics in
determining the long-term health and viability of an organism. Fascinatingly, TORC1
may lie at the center of all three of these. It is clear that as an organism ages, a number of
pathologies become more prevalent, including cardiovascular disease, cancer, diabetes
and dementia. These diseases are all believed to be driven at some level by mTORC1
hyperfunction, which is itself a result of aging [289]. But it remains unclear as to why
overactive mTORC1 has such a profound effect on cellular physiology and longevity.
The apparent association of TORC1, sirtuins and chromatin dynamics is
intriguing as they have all been heavily cited as regulators of aging. Yet to our
knowledge, there is very minimal mechanistic understanding to link all three. Inhibition
of TORC1 with rapamycin or CR extends lifespan [68, 70-74, 290], activation of sirtuin
function through treatment with resveratrol mimics these effects [67, 157-159, 291], and
deletion of sirtuins dramatically reduces lifespan [170, 292]. This fact is incredibly
important because we will present data showing that TORC1 inhibition promotes sirtuin
function and histone deacetylation through a novel subcellular accumulation and
stabilization mechanism. Such a relationship could also explain why there is controversy
regarding which target (mTor vs. sirtuins) would be best to pursue in slowing or
reversing cellular aging (as reviewed by Sinclair) [290].
The majority of tissues in the body consist of a large population of post-mitotic,
fully-differentiated cells, and a smaller stem cell niche tasked with replenishing and
maintaining the population over time. Classical aging phenotypes are most often
attributed to cellular chronological aging, which is marked by an overall decline in cell
health and function, culminating in physiological defects on the organismal scale. Recent
evidence in skeletal muscle and the brain suggests that the longevity and viability of both
the long-lived post-mitotic populations, as well as their stem cell niches, depends on
sustained maintenance of chromatin as cells mature/age. Jurk et al. demonstrate that upon
proliferative cessation, mature neurons enter a senescent-like state marked by
heterochromatinization, elevated ROS production, persistent DNA damage, and other
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traditional indicators of the senescence-associated secretory phenotype [293]. These
effects become more prominent and deleterious with age but can be partially reversed by
CR. And although the authors do not address the nature of this effect, it does suggest the
possibility that nutrient responsive TORC1 function may contribute to the development
of age-related senescence. We are particular fascinated with the chromatin effects
observed in these cells, because it is now known that chromatin states in non-mitotic
neurons are not nearly as static as they once seemed [294-297]. Gong et al. show that in
aging mouse brains, there is a notable shift in the epigenetic landscape, including the
acetylation and methylation of H3/H4, and many of these same modifications are
responsive to CR or rapamycin treatment [298]. Liu et al. report that maintenance of
quiescence in skeletal muscle stem cells correlates to a unique epigenetic signature which
degrades with age [299]. Corruption of these signatures, specifically a genome-wide
overrepresentation of H3K27me3, results in heterochromatin accumulation which the
authors speculate contributes to an observed loss of stem cell function with age.
The above demonstrates how chromatin deregulation contributes to loss of
function in vital cell populations, which ultimately results in organismal aging. It is the
goal of this dissertation to characterize the mechanism by which TORC1 activity affects
these processes, and to evaluate their potential contribution to organismal viability and
longevity. In other words, to functionally understand the intersection between an
organism’s environment, lifestyle, and epigenome as it relates to health and longevity.
The project presented below is guided by the following Specific Aims:
(1) Define the contribution of TORC1 signaling to the regulation of histone
acetylation modifications and elucidate the mechanisms involved.
(2) Determine the impact that TORC1-regulated histone acetylation has on
cellular functions.
(3) Define the role of the poorly-understood TORC1 subunit Tco89 in TORC1
signaling and epigenetic regulation.
Addressing these Specific Aims will provide significant insight into TORC1-dependent
coordination of epigenetic mechanisms under normal biological conditions, while also
identifying how TORC1 dysfunction and epigenetic corruption may contribute to disease
mechanisms on an organismal scale.
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CHAPTER 2.

MATERIALS AND METHODOLOGY

Yeast Strains, Plasmids, and Culture Conditions
All of the yeast strains and plasmids used in this work are described in Tables
A-1 and A-2 (in Appendix A), respectively. Strains constructed in our lab, including
gene deletions and epitope tags, were made using PCR-generated targeting cassettes as
previously described [300]. Unless otherwise stated, cells were grown in YPD (1% yeast
extract, 2% peptone, and 2% dextrose) at 30° C with shaking. For experiments conducted
in synthetic complete media, dropout mix was incorporated and supplemented with the
appropriate amino acids to compensate for the auxotrophy of the strains. All media
components were purchased from US Biologicals or Research Products International
(RPI). Phos-tag was purchased from Wako Chem. Rapamycin, nicotinamide, sodium
butyrate, trichostatin A, L-methionine sulfoximine (MSX), 2-(N-morpholino)
ethanesulfonic acid (MES), and caffeine were purchased from either Fisher Scientific or
Sigma-Aldrich. Galactose was purchased from MP Biomedical. The concentrations of
these reagents are noted in the text.
Cloning primers for Tco89 fragmentation and Tco89/Sit4 complementation
studies were designed as discussed in the text and as previously described [300]. The
open reading frames of TCO89 and SIT4 were cloned as C-terminal mono-FLAG fusions
into the BamHI/XbaI (Tco89FL and fragments) or BamHI/EcoRI (Sit4FL) restriction
sites of the pRS416ADH plasmid, which contains an ADH1 promoter and CYC1
terminator [301]. PSI/PRED prediction software was used to avoid disruption of any
potential secondary amino acid structure (discussed in Chapter 5) [302]. See Table A-2
for more information.
Antibodies and Stains
Antibodies used in this work were obtained from the following; α-RPS6 (Abcam),
α-phosphoS6 (Cell Signaling), α-FLAG (Stratagene), goat α-rabbit HRP conjugated
secondary (Jackson), α-Myc 4A6 (Millipore), α-HA and α-Myc A14 (Santa Cruz),
G6PDH (Sigma), α-FLAG (Thermo), goat α-rabbit FITC-conjugated secondary
(Rockland). Histone antibodies were all obtained from Active Motif. IgA- and IgGconjugated beads for immunoprecipitation were from Santa Cruz. For live cell work,
5(6)-Carboxyfluorescein diacetate (CFDA) vacuolar stain was obtained from Invitrogen,
dihydroethidium (DHE) from Fisher, and Hoechst nuclear stain from Life Technologies.
For fixed cells, the Vectashield mounting media containing DAPI was purchased from
Vector Labs. The apoptosis and necrosis staining experiments were conducted using an
AnnexinV-FITC apoptosis kit from Clontech, and YO-PRO-1, propidium iodide (PI) and
SYTOX from Life Technologies.
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Western Blotting and Statistical Analysis
Cells were grown to log phase (OD600 ≈0.8) in the indicated media as described
above prior to treatment with drug (rapamycin or MSX) or galactose (2% final
concentration), unless noted. Typically, cultures were set up to double 3 to 4 times before
reaching this OD, ensuring that the majority of cells were replicatively young and
metabolically active. Cells were then transferred to 50 mL falcon tubes using sterile
technique, pelleted in a tabletop centrifuge, and frozen at -80°C. Pellets were resuspended
in pre-chilled cracking buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40,
10% glycerol, 1 mM DTT) with additional phosphatase, histone deacetylase, and protease
inhibitors. Glass beads were added to each tube, and the cells were lysed using a coldroom bead beater (3x 30 sec pulse with 3 min on ice in-between). Supernate was clarified
at 4°C and stored at -80°C. Extract concentrations were determined using a traditional
Bradford assay, and 35 μg samples were resolved by SDS-PAGE and transferred to
PVDF membrane. In the case of samples subjected to SDS-PAGE with Phos-tag additive
(50 μM), the included manufacturer’s instructions were followed. Membranes were
probed overnight at 4°C with primary Ab. The blots were washed in TBST (10% TBS,
0.1% tween) for at least an hour with buffer replacement every 15 minutes. The blots
were then incubated in secondary Ab for between 2 and 4 hours before developing using
autoradiography. Films were scanned and analyzed by ImageJ where denoted. For
determining significance, we used a two-tailed, unequal variance, pairwise Student’s ttest. *p<0.05, **p<0.01, ***p<0.001.
Spotting Assays
Cells were grown overnight at 30°C with shaking to saturation. OD600 readings
were taken and equivalent numbers of cells were aliquoted into column A of a sterile 96well culture plate (see formulas below). The volumes in column A were made up to 200
μL with sterile water.
ߤ ݏ݈݈݁ܿܮൌ

ʹͲͲ
ߤܪܮଶ ܱ ൌ ʹͲͲ െ ߤݏ݈݈݁ܿܮ
ܱܦ ݁ݎݑݐ݈ݑܿݕݎܽ݊݅ݐܽݐݏ݂

Five-fold serial dilutions were then performed in which 40 μL of column A were
transferred into 160 μL of water in column B and so forth. Cells were spotted to plate
media and incubated as noted. Images were taken daily for 5-7 days using a UVP Digital
Imaging System.
RT-qPCR
cDNA was synthesized from DNase I treated cellular RNA using random
hexamer primers and the ImProm II reverse transcriptase system from Promega. Gene
specific qPCR was conducted and normalized to the SPT15 housekeeping gene as
previously described [303]. Primers are available upon request.
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Indirect Immunofluorescence Confocal Microscopy
For studies regarding sirtuin localization, the following technique was utilized.
First, cells were grown to log phase and treated as indicated. The cells were then fixed
with 37% formaldehyde, pelleted at 800xg for 4 minutes, and washed twice with 4 mL of
0.1 M potassium phosphate buffer (K2HPO4, pH=6.5) and once with 4 mL P solution (1.2
M sorbitol, 0.1 M K2HPO4, pH=6.5). Pellets were then gently resuspended in 1 mL P
solution and incubated at room temperature with 15 μL zymolase (15 mg/mL in P
solution) and 5 μL β-mercaptoethanol for 25 minutes. Cell wall digestion
(spheroplasting) was confirmed using a phase contrast microscope. After spheroplasting,
cells were gently pelleted and resuspended in 150 μL of P solution. The resulting
suspension was aliquoted to a poly-lysine coated slide and cells were allowed to settle for
20 minutes prior to blocking (8% bovine serum albumin/PBS/0.5% Tween 20). Slides
were then placed in a humidified chamber and incubated in primary antibody overnight at
4°C. Following primary incubation, slides were washed four times with blocking
solution, prior to the addition of fluorophore-conjugated secondary antibody (60 minutes
at room temperature). From here on slides were protected from light. After the secondary
incubation, slides were washed four times with blocking solution and twice with PBS.
Finally, a drop of DAPI-containing Vectashield mounting media was placed on the slides
and coverslips were positioned and sealed. Samples were imaged with the 63x oil
Olympus objective on a Zeiss LSM 700 confocal microscope.
Direct Immunofluorescence Confocal Microscopy
For studies measuring HMG localization, cells were grown to log phase in
duplicate 10 mL cultures and treated as indicated. Treatments often occurred over 60
minutes, so immediately following addition of drug, the process to image the untreated
cells began. Untreated cells were spun down, washed with sterile water, transferred to a
microfuge tube and pelleted. The cells were then resuspended in 100 μL sterile water
with 2 μL Hoechst and incubated with agitation away from light for 15 minutes. Finally,
the untreated cells were spun down, resuspended in 10 μL sterile water with 0.5 μL
Hoechst and cover slipped as quickly as possible to avoid effects the altered nutrient state
may have on the results. Slides were imaged with the 63x oil Olympus objective on a
Zeiss LSM 700 confocal microscope. Following the one hour incubation of the treated
cells, the above steps were repeated.
Image Analysis in Zen 2 Blue
In order to quantitate the subcellular localization of the tagged proteins, images
taken on the Zeiss LSM 700 were analyzed in the Zen Lite Version 2.0.0 software
program (blue edition) as previously described [304]. Briefly, using the Spline Contour
tool, a border was drawn around the outer edge of each cell. Then, a second border was
drawn around the nucleus. Upon closure of each border, information was provided,
including the area within the border, and the mean intensity of each channel inside that
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space. The mean intensity value for the green channel within the nucleus was multiplied
by the area within the nuclear border to obtain our total nuclear fluorescence intensity
(TNFI).
ܶܰ ܫܨൌ ݊ܽ݁ݎܽݎ݈ܽ݁ܿݑ݊ כ ݁ݑ݈ܽݒݕݐ݅ݏ݊݁ݐ݊݅݊ܽ݁݉ݎ݈ܽ݁ܿݑሺ݊݉ଶ ሻ
This calculation was repeated for the values from the outer cell border, providing
us a value we refer to as the total cellular fluorescence intensity (TCFI).
ܶ ܫܨܥൌ ݈݈ܿ݁ܽ݁ݎܽݎ݈ܽݑ݈݈݁ܿ כ ݁ݑ݈ܽݒݕݐ݅ݏ݊݁ݐ݊݅݊ܽ݁݉ݎ݈ܽݑሺ݊݉ଶ ሻ
From there, we simply divided the total nuclear intensity by the total cellular
intensity and multiplied by 100 to get the percentage of our protein of interest that resides
in the nucleus.
Ψ݊ ݎ݈ܽ݁ܿݑൌ

ܶܰܫܨ
ͲͲͳ כ
ܶܫܨܥ

Analysis fields were chosen at random, with approximately 20-40 cells quantified
per condition, per independent biological replicate (4-6 replicates). Cells with a cellular
mean intensity value under 50 units were excluded from calculations as we believe this is
the threshold of adequate immunostaining.
Sirtuin Turnover/Half-Life Analysis
Cells were grown to log phase in 200 mL YPD flasks. At T0, 50 mL aliquots were
sterilely sampled from each sample, pelleted, and frozen. Cycloheximide (CHX) was then
added to each flask at a concentration of 100 μg/mL. 50 mL aliquots were retained as
described above at the time points indicated. Whole cell extracts (WCEs) were prepped
and analyzed by α-Myc immunoblot. Films were scanned, quantified with ImageJ, and
sirtuin signals were normalized to total protein via G6PDH.
Apoptosis, Necrosis, DHE and CFDA Assays
For analysis of apoptosis and necrosis, log phase cells were pelleted, washed
twice with sterile PBS, and incubated for 20-30 minutes in the respective dyes: PI (50
μg/mL) and YO-PRO-1 (10 μM). Cells were then transferred to flow cytometry tubes,
processed on a BD LSRII flow cytometer, and analyzed using FLOWJO V10. DHE (30
μM) and CFDA (100 μM) staining experiments were identical to the above except for the
use of the different stains, and the retention of cells for additional confocal analysis.
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Scoring for Tco89 Fragment Phenotypes
WT and tco89Δ cells were transformed with control vector or Tco89 N-terminal
truncation fragments as indicated, grown to saturation, and spotted as detailed previously
(see “Spotting Assays” section of this chapter). Growth on the spotting plates was scored
as described by Rizzardi et al. [305]. Briefly, mutants were scored on a scale of -3 to 3,
with a score of 1 representing an approximate 5-fold difference in growth and a value of
3 being a 125-fold difference. Strains exhibiting growth defects compared to wild-type
cells received a negative value, while those with enhanced growth were given a positive
value. A value of 0 indicates growth essentially equivalent to the control. Scores from at
least five independent transformations were averaged, and a heat map was constructed in
Microsoft Excel.
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CHAPTER 3. TORC1 FUNCTION MAINTAINS HISTONE ACETYLATION
BY OPPOSING THE SIT4-DEPENDENT NUCLEAR ACCUMULATION OF
SIRTUINS1
TORC1 Mediates Site-Specific Histone H3 and H4 Acetylation in Response to
Environmental Stress, Particularly Glutamine Starvation
Our previous work identified a connection between TORC1 and the control of
global H3K56ac [66]. We wanted to determine whether this effect was unique to
H3K56ac, or if TORC1 also regulated other acetylation states on the histone H3/H4 tails.
To do so, wild-type and tco89Δ cells were grown to log phase and wild-type cells were
either mock or rapamycin treated (300 nM) for 60 minutes. The concentration and length
of rapamycin treatments selected were confirmed to diminish TORC1 activity by
phosphoS6 blot (Figure B-1 in Appendix B). WCEs prepared from these samples were
screened for alterations to distinct histone acetylation states by immunoblotting (IB) with
the indicated antibodies (Figure 3-1A). Films were scanned and analyzed by ImageJ, and
relative histone acetylation was calculated by normalizing to total H3 with the mock
treated samples set to 1 (graphed in Figure 3-1B). As shown in Figure 3-1A, TORC1
inhibition resulted in a dramatic site-specific reduction of acetylation at H3K18
(H3K18ac), H3K23 (H3K23ac), and H4K12 (H4K12ac), while other acetylation states
were unaffected. These changes cannot be attributed solely to downregulation of
transcription-coupled marks as we find that H3K4me3, a histone modification that
demarcates actively transcribed genes, was unaffected. Loss of these histone
modifications is unlikely to be explained by indirect consequences of TORC1 inhibition,
since the acetylation reduction was observed as early as 20 minutes post-rapamycin
treatment (Figure 3-1C). Furthermore, we demonstrated that exogenous Tco89
expression in the tco89Δ rescued acetylation, thus confirming that reduction of histone
acetylation was due solely to the loss of this TORC1 subunit (Figure 3-1D).
Nitrogen metabolism, described in Chapter 1, is an established activator of
TORC1 via the vacuolar-localized EGO and v-ATPase complexes. Prior evidence
suggested carbon metabolism may regulate many of the histone acetylation states
identified in Figure 3-1A [306]. Therefore, we next compared the impact of these
nutrient signals on our sites of interest to determine whether the mechanisms which link
carbon and nitrogen to the epigenome are overlapping, via TORC1, or are distinct. We
first utilized the glutamine synthetase inhibitor MSX to block glutamine biosynthesis and
impair nitrogen metabolism (Figure 3-2A). Treatment with 2 mM MSX mimicked the
decrease in H3K18ac that occurs in response to direct TORC1 inhibition (Figure 3-2B,
upper panel and graph). We confirmed MSX treatment reduced TORC1 activity by αphosphoS6 IB (Figure 3-2B, lower panel). However, changing the quality of the carbon
source from glucose to non-fermentable carbon (glycerol) failed to affect acetylation in
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Modified with permission from Genetics Society of America. Workman, J.J., H. Chen, and R.N. Laribee,
Saccharomyces cerevisiae TORC1 Controls Histone Acetylation by Signaling Through the Sit4/PP6
Phosphatase To Regulate Sirtuin Deacetylase Nuclear Accumulation. Genetics, 2016.
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Figure 3-1. TORC1 signaling coordinates site-specific lysine acetylation on a
subset of histone H3 and H4 N-terminal residues.
A. Wild-type (WT) and tco89Δ cells were grown to log phase and subjected to mock or
300 nM rapamycin treatment for 60 minutes. Cells were harvested and whole-cell
extracts (WCEs) were analyzed by immunoblot (IB) with the indicated antibodies. B.
ImageJ quantification of the results from (A). Data are representative of four or more
biological replicates. Means and standard deviations (SDs) are provided, and significance
was determined by pairwise Student’s t-test. *-p<0.05; **-p<0.01; ***-p<0.001. C. As in
(A), except WT cells were treated with 200 nM rapamycin for 20 minutes. D. WT and
tco89Δ cells were transformed with control vector (CV) or Tco89-9xMyc expression
vectors and WCEs were analyzed as in (A).
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Figure 3-2. TORC1-dependent histone acetylation is responsive to nitrogen, but
not carbon, limitation.
A. Schematic showing the step in the glutamine biosynthetic pathway inhibited by MSX
[307, 308]. B. WT cells were cultured to log phase and then mock treated or treated with
2 mM MSX for 20 minutes. Cells were harvested and extracts were analyzed by
immunoblot with the indicated antibodies. ImageJ quantification was conducted, and a
graphical representation of the mean and SD obtained over 9 independent experiments is
provided. Significance was determined by pairwise Student’s t-test. ***-p<0.001. C. WT
and tco89Δ cells were grown to log phase in YP 2% glucose or YP 2% glycerol. Extracts
were prepared as above and blotted with the indicated antibodies.
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either the wild-type or the tco89Δ mutant (Figure 3-2C). Given that cells grow more
slowly in non-fermentable carbon, these findings also ruled out the possibility that the
acetylation differences in tco89Δ are attributable to the reduced growth rate of this
mutant. All together, these findings suggest a mechanism in which TORC1 activation, in
response to nitrogen metabolism, functions to regulate this subset of histone acetyl sites.
TORC1 Signals through the Tap42-Sit4 PP6 Phosphatase Complex to Regulate SiteSpecific Histone Acetylation Globally
After defining the TORC1-regulated histone acetylation states on histones H3 and
H4, we next wanted to identify which TORC1 downstream effector was responsible for
mediating these changes. Initially, we examined whether the TORC1-activated Sch9
kinase contributed to the control of these histone modifications using a series of
previously described Sch9 expression vectors [80]. These included vectors expressing
wild-type Sch9 (Sch9WT), a mutant form of Sch9 in which the TORC1 phosphotarget
sites have been changed to alanines to prevent activation (Sch95A), and another mutant
Sch9 with those same sites mutated to acidic residues to mimic constitutive TORC1dependent Sch9 phosphorylation (Sch92D3E). We first demonstrated that wild-type and
mutant Sch9 were expressed at relatively similar levels, thus ruling out the possibility that
these mutations altered protein stability (Figure B-2A). From there, a series of control
experiments were conducted, beginning with confirmation that in an sch9Δ mutant,
introduction of the Sch92D3E plasmid enabled growth on non-preferred carbon sources
and rapamycin (Figure B-2B). We also determined that the mutant plasmid promotes
Maf1 phosphorylation (a direct substrate of Sch9) regardless of upstream TORC1 activity
(Figure B-2C) [87]. These findings confirmed that the Sch92D3E mutant did behave
independently of TORC1 as expected. Introduction of the Sch92D3E mutant into tco89Δ
failed to rescue acetylation (Figure 3-3A). Furthermore, histone acetylation was not
reduced in sch9Δ (Figure 3-3B). We conclude that the Sch9 kinase does not function
downstream of TORC1 to regulate histone acetylation.
We next investigated whether the other well-characterized downstream TORC1
effector, Tap42, contributes to the regulation of histone acetylation. TAP42 is an essential
gene, so we utilized tap42Δ cells possessing a plasmid-based temperature-sensitive (ts)
Tap42 allele [309]. In Figure 3-4A, we confirmed these three ts strains are indeed acutely
sensitive to heat stress. We chose to specifically analyze the tap42Δ+tap42-106ts mutant
as it had the least dramatic temperature sensitivity, which we predicted would limit nonspecific acetylation changes due to impaired viability. Wild-type and tap42-106ts mutant
cells were grown to log phase at the permissive (25°C) temperature and then shifted to a
non-permissive condition (30°C) for 1 hour. WCEs were prepared and histone acetylation
was analyzed by IB. Strikingly, in cells whose TORC1 function was intact, simply
inactivating Tap42 led to dramatically reduced H3K18ac (Figures 3-4B and C). Even at
the permissive temperature, there was a specific reduction in TORC1-regulated H3K18ac
but no effect on H3K9ac, which we know is not responsive to TORC1 (Figure 3-1A).
These results demonstrate that TORC1 likely signals through a Tap42-associated
phosphatase to regulate site-specific histone acetylation.

31

Figure 3-3. Regulation of histone acetylation downstream of TORC1 occurs
independently of the Sch9 kinase.
A. Wild-type (WT) and tco89Δ cells were transformed with control vector (CV) or
Sch92D3E-expression vector and grown to log phase in selective media before preparation
of WCEs. Extracts were analyzed by immunoblot with indicated antibodies. B. WT,
tco89Δ and sch9Δ cells were grown in YPD and WCEs were prepared. Analysis by
immunoblot was conducted as indicated. Western blots and histone acetylation averages
provided are representative of at least three independent experiments, normalized to H3,
with corresponding WT samples set to 1.
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Figure 3-4. TORC1-responsive histone acetylation is regulated in a Tap42dependent fashion.
A. tap42Δ cells containing endogenously expressed wild-type Tap42, or various
temperature sensitive mutants (tap42-11, -109, -106) [309], were grown to saturation,
five-fold serially diluted, and spotted onto YPD. Plates were cultured at permissive
(25°C), semi-permissive (30°C), and non-permissive (33°C) temperatures and images
were taken on day 2. B. Cells from (A) were grown to log phase in liquid culture at 25°C
before being shifted to 30°C for 1 hour. WCEs were prepared and analyzed by
immunoblot. C. Quantification of results presented in (B). Data is representative of three
biological replicates. Means and SDs are provided, and significance was determined by
pairwise Student’s t-test. **-p<0.01; ***-p<0.001.
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The Tap42-associated phosphatases are organized into modular complexes.
Typically, they are structured such that Tap42 associates with a catalytic subunit, and one
or more regulatory subunits. To identify which of the phosphatases is required for
TORC1-regulated acetylation, we screened catalytic mutants of individual Tap42associated phosphatase complexes (PPG1/ppg1Δ, PP4/pph3Δ, and PP6/sit4Δ) for the loss
of rapamycin-induced deacetylation. Since PP2A possesses redundant catalytic subunits
(Pph21 and Pph22), we instead used a tpd3Δ mutant, which eliminates the PP2A
regulatory subunit and impairs PP2A function [310]. Notably, only deletion of SIT4, the
catalytic subunit of the PP6 phosphatase complex, prevented the rapamycin-induced loss
of H3K18ac (Figure 3-5A). We saw an identical effect on H3K56ac in sit4Δ cells before
and after rapamycin, strengthening our hypothesis that TORC1 is mediating H3K18ac,
H3K23ac, H3K56ac and H4K12ac through a conserved mechanism. Importantly, we
show in Figure 3-5B that transformation of the sit4Δ mutant with a Sit4 expression
vector was sufficient to restore the rapamycin sensitivity of H3K18ac. Finally, the tco89Δ
acetylation defect was completely rescued in a sit4Δ tco89Δ combinatorial mutant
(Figure 3-5C), further demonstrating that TORC1 inhibition promotes loss of histone
acetylation through the activation of the Sit4 phosphatase.
The PP6 complex is a heterotrimer consisting of Tap42, Sit4, and one of four
Sit4-associated regulatory proteins (Saps). To probe whether a particular Sap was
responsible for Sit4-dependent acetylation repression, we conducted a similar experiment
as described in Figure 3-5A, except individual Sap deletions were screened. Loss of
either the Sap4 (sap4Δ) or Sap185 (sap185Δ) subunits led to significant rescue of
acetylation in rapamycin-treated samples (Figure 3-6). However neither mutant alone
was sufficient to promote the rapamycin resistance observed in a sit4Δ (Figure 3-5A).
This suggests that while Sap4 and Sap185 are most likely linked to Sit4-dependent
regulation of acetylation, there appears to be a degree of functional redundancy between
the Saps in this regard.
Sit4’s best-known function in the cell is to regulate the NCR response by
modulating the phosphorylation, and subsequent localization, of the transcription factors
Gln3 and Gat1 [75, 113, 145]. When cells are starved for amino acids, Gln3 dissociates
from the cytoplasmic anchor Ure2 and moves to the nucleus in a Sit4-dependent fashion.
Nuclear Gln3 then activates transcription of genes required for the utilization of nonpreferred nitrogen sources. Because TORC1 suppression promotes Gln3 nuclear
localization through Sit4 activation, we probed whether induction of the NCR was
required for the effect on histone acetylation.
While loss of Sit4 led to an increase in basal H3K18ac as expected, we found
surprisingly that deletion of the NCR transcription factors, Gln3 or Gat1, did not result in
a similar increase in acetylation (Figure 3-7). In support of the above, loss of the
cytoplasmic anchor Ure2 did not phenocopy the tco89Δ hypoacetylation response
(Figure 3-7). Taken together, these data suggest that the PP6 protein phosphatase
complex is responsible for connecting TORC1 to the regulation of histone acetylation and
that Sit4’s contribution exists outside of the NCR response.
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Figure 3-5. Sit4-catalyzed PP6 complex activity is required for TORC1responsive histone acetylation.
A. Wild-type (WT), tpd3Δ, ppg1Δ, pph3Δ and sit4Δ cells were grown in YPD to log
phase before treatment with 300 nM rapamycin for 60 minutes. WCEs were prepared and
analyzed by immunoblot and ImageJ. B. WT cells transformed with control vector (CV)
and sit4Δ cells transformed with CV or full-length pSit4-FLAG, were grown to log phase
in selective media and treated with rapamycin as in (A). Extracts were prepped and
probed by immunoblot. C. WT, tco89Δ, sit4Δ and tco89Δ sit4Δ were grown to log phase,
extracts were prepared and blotted as described above. Data are representative of at least
3 independent replicates, with average histone acetylation values relative to H3 (mock set
to 1) provided.
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Figure 3-6. Regulatory subunits of the PP6 phosphatase complex display
overlapping function in relation to TORC1-responsive histone acetylation.
As in Figure 3-5A, except mutants are various Sit4-associated protein (SAP) deletions,
including sap4Δ, sap155Δ, sap185Δ and sap190Δ. Blots are representative of at least 3
independent replicates and average histone acetylation values relative to H3 (mock set to
1) are provided.

Figure 3-7. Sit4-dependent, nitrogen-responsive chromatin modifications are
separable from the canonical nitrogen catabolite response (NCR) pathway.
Mutants of the Sit4-mediated NCR stress response, including ure2Δ, gln3Δ and gat1Δ,
were grown to log phase alongside WT, tco89Δ and sit4Δ, and analyzed by immunoblot
as indicated. Blots are representative of 3 independent replicates and average histone
acetylation values relative to H3 (WT set to 1) are provided.
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TORC1-Responsive Histone Acetylation Is Specifically Regulated by the Sirtuin
Histone Deacetylases
In our previous analysis of TORC1-dependent regulation of H3K56ac, we
reported that loss of either of the sirtuins, Hst3 or Hst4, in a tco89Δ background restored
acetylation to wild-type levels. This prompted us to investigate whether these newly
identified TORC1-dependent acetylation states were similarly regulated. Initially, we
cultured wild-type and tco89Δ cells to log phase and mock treated or treated with
nicotinamide, a naturally occurring pan-sirtuin inhibitor. Treatment with nicotinamide led
to an increase in basal H3K18ac in wild-type cells, and also rescued the acetylation
defect observed in tco89Δ (Figure 3-8A). Strikingly, tco89Δ cells treated with FK866, a
compound which inhibits sirtuins by blocking NAD+ biosynthesis [311], displayed robust
restoration of histone acetylation (Figure 3-8B, left panel). The effect of FK866 on
acetylation in wild-type cells was negligible. A pathway exists in yeast by which active
TORC1 represses transcription of PNC1, a gene which encodes a nicotinamidase that
scavenges nicotinamide and shunts it into the NAD+ biosynthetic cycle [67]. This means
that TORC1 suppression results in both a reduction in the level of sirtuin inhibitor
(nicotinamide), as well as an increase in sirtuin co-factor availability (NAD+). We next
asked whether increased PNC1 expression could explain our observed link between
TORC1 and sirtuin-dependent histone deacetylation. Surprisingly, combining pnc1Δ with
tco89Δ failed to rescue TORC1-dependent acetylation (Figure 3-8B, right panel).
To probe whether class I or II histone deacetylases were also contributing to the
regulation of TORC1-dependent acetylation states, we initially utilized the
pharmacological inhibitors sodium butyrate and trichostatin A. However, for unknown
reasons, these compounds failed to provide effective HDAC inhibition (data not shown).
To circumvent this issue, we combined tco89Δ with a gene deletion of the major class I
(Rpd3) or class II (Hda1) histone deacetylases to ask whether loss of these HDACs would
diminish TORC1-dependent deacetylation. While the rpd3Δ and hda1Δ single mutants
displayed elevated acetylation across our residues of interest, combining these with a
tco89Δ still led to a significant reduction in acetylation (Figure 3-9, compare 2nd and 4th
lanes). These results further support the hypothesis that TORC1-dependent histone
acetylation specifically involves suppression of the sirtuins. To gain a more complete
understanding as to the contributions of each sirtuin, we created another set of
combinatorial mutants that paired tco89Δ with individual sirtuin deletions. These strains
were used to repeat the experiment in Figure 3-9. Strikingly, we found dramatic
differences in the ability of these sirtuin deletions to rescue site-specific acetylation in
tco89Δ (Figure 3-10A and B). For example, H3K18 is deacetylated primarily by Hst2,
Hst3 and Hst4, while H3K23 is solely targeted by Hst4. In all, our findings support the
idea that active TORC1 promotes acetylation of the H3/H4 N-termini via repression of
the Sit4/Sap4 PP6 phosphatase and the sirtuin deacetylases, and that this novel
mechanism does not involve changes in Pnc1 levels or NAD+ biosynthesis.
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Figure 3-8. TORC1-PP6 catalyzed histone H3/H4 deacetylation is promoted by
the NAD+-dependent sirtuin family of histone deacetylases.
A. Wild-type (WT) and tco89Δ cells were grown to log-phase before mock or 25 mM
nicotinamide (sirtuin inhibitor) treatment for 60 minutes. WCEs were prepared and
immunoblotted as indicated. Blots are representative of 3 independent replicates and
average histone acetylation values relative to H3 (WT mock set to 1) are provided. B. In
left panel, as in (A) except cells were treated with 500 nM FK866. In right panel, WT,
tco89Δ, pnc1Δ and tco89Δ pnc1Δ were grown and analyzed by immunoblot as indicated.

Figure 3-9. Class I and II histone deacetylases are not involved in the observed
TORC1-PP6 hypoacetylation response.
WT, rpd3Δ, tco89Δ, tco89Δ rpd3Δ, hda1Δ and tco89Δ hda1Δ were grown to log-phase.
Extracts were prepped and analyzed by immunoblot. Blots are representative of 4
independent replicates.
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Figure 3-10. TORC1-responsive histone acetylation is modulated by a subset of
sirtuin histone deacetylases in a site-specific fashion.
A. Combinatorial tco89Δ sirtuin gene deletion mutants were grown and analyzed by
immunoblot as indicated. B. ImageJ quantification of data shown in (A). Data are
representative of at least four biological replicates. Means and SDs are provided, and
significance was determined by pairwise Student’s T-test. *-p<0.05; **-p<0.01; ***p<0.001.
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Sit4 Activation Downstream of TORC1 Inhibition Promotes Hst4 Stabilization
Mammalian mTORC1 activity was previously shown to regulate glutamine
metabolism and TCA cycle replenishment by transcriptional suppression of SIRT4 [184].
We speculated that TORC1 inhibition in yeast might function similarly by promoting
deacetylation through an increase in sirtuin expression. To address this, we epitopetagged the sirtuin genomic loci with a 9xMyc epitope in both WT and tco89Δ cells. Cells
were grown, WCEs prepared, and expression was analyzed by immunoblot. We observed
dramatic increases in Hst4 and Sir2 protein expression in the tco89Δ mutants relative to
wild-type cells (Figure 3-11A). Given that we previously identified Hst4 as the only
sirtuin able to control all of the TORC1-dependent acetylation modifications (Figure
3-10), we selected it for further examination across a variety of TORC1 inhibitory
conditions. Short-term rapamycin and MSX treatment had no effect on Hst4 levels in
wild-type cells; however, both tco89Δ and 60-minute exposure to rapamycin led to
elevated Hst4 expression compared to the mock-treated wild-type cells (Figure 3-11B).
Considering that 20-minute TORC1 inhibition was sufficient to reduce histone
acetylation (Figures 3-1C, 3-2B), we were surprised to find that Hst4 levels did not
significantly increase until later in the treatment period.
To assess the contribution of Sit4 to these dynamic changes in Hst4 protein levels,
we engineered sit4Δ and tco89Δ sit4Δ into the Hst4-9xMyc background and again
examined Hst4 expression. Excitingly, we found that deletion of SIT4 in the wild-type
Hst4-tagged strain significantly reduced Hst4 levels, and the combinatorial mutant,
tco89Δ sit4Δ, brought the elevated Hst4 levels observed in the tco89Δ single mutant back
to approximately wild-type levels (Figure 3-11C, upper panel). We saw a much more
muted response when the experiment was repeated with a series of sap4Δ mutants, a
result consistent with the idea that there is functional redundancy among the Saps
(Figure 3-11C, lower panel). Given TORC1’s known role in regulating transcription, we
used qPCR and confirmed that the increase in Hst4 protein levels was not due to elevated
HST4 mRNA expression (Figure 3-12). Therefore, these data suggest that the Sit4dependent effect on Hst4 expression is either translational or post-translational in nature.
Hst3 exhibits rapid proteasomal turnover, in a cell-cycle dependent fashion, in
response to Cdk1 phosphorylation and subsequent SCFCdc4 ubiquitination [179, 180]. The
phosphatase that opposes Cdk1-dependent Hst3 turnover is currently unknown. Hst4 was
also identified as a potential SCFCdc4 substrate, but its proteolytic turnover has not been
studied in nearly as much detail. We next asked whether the Sit4-dependent increase in
Hst4 protein levels could be explained by a reduction in Hst4 turnover. To assess this
possibility, we utilized our wild-type and tco89Δ strains expressing Hst4-9xMyc, and we
examined the kinetics of Hst4 turnover in each. Cells were grown to log phase and then
treated with cycloheximide (CHX), an inhibitor of protein synthesis. Excitingly, we
found that relative to wild-type cells, the tco89Δ promoted a significant increase in Hst4
stability (Figure 3-13A). We demonstrate this stabilization is Sit4-dependent, as the
tco89Δ sit4Δ Hst4-9xMyc strain displays a turnover rate very similar to that of the wildtype. We conducted the same experiment with WT and tco89Δ strains possessing an
Hst3-9xMyc epitope for comparison, and surprisingly, found that in addition to the
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Figure 3-11. Reduced TORC1 signaling activates PP6 to increase Hst4 protein
levels.
A. No tag, and WT or tco89Δ cells expressing indicated epitope-tagged sirtuins, were
grown to log phase and analyzed by IB with Myc or G6PDH antibodies. B. No tag, WT
Hst4-9xMyc, and tco89Δ Hst4-9xMyc cells were grown to log phase before treatment
with MSX or rapamycin as indicated. WCEs were blotted for Myc and G6PDH and
analyzed by ImageJ. Quantification of Hst4 levels relative to G6PDH are provided with
the WT mock set to 1. C. No tag, WT Hst4-9xMyc, sit4Δ Hst4-9xMyc, sap4Δ Hst49xMyc, tco89Δ Hst4-9xMyc, tco89Δ sit4Δ Hst4-9xMyc, and tco89Δ sap4Δ Hst4-9xMyc
cells were grown to log phase and analyzed as in (B). Blots and expression values are
representative of at least 3 independent biological replicates.
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Figure 3-12. PP6-dependent changes in Hst4 protein levels are not due to increased
HST4 mRNA expression.
Hst3, Hst4 and Sir2 mRNA expression in wild-type, tco89Δ, hst4Δ, and tco89Δ hst4Δ
cells. Means and SDs are presented and the data is representative of five independent
experiments. Significance was determined by pairwise Student’s T-test. **-p<0.01; ***p<0.001.
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Figure 3-13. PP6 activation downstream of TORC1 inhibition initiates a reciprocal
shift in Hst3/Hst4 stability.
A. No tag, WT Hst4-9xMyc, tco89Δ Hst4-9xMyc and tco89Δ sit4Δ Hst4-9xMyc cells
were grown to log phase and treated with 50 μg/mL cyclohexamide (CHX). Samples
were taken just before CHX addition and then at subsequent intervals. Two exposures of
the α-Myc blot are provided for clarity, and data quantification is shown on the right.
Values are the mean and SD of four independent biological replicates, and significance
was determined by pairwise Student’s t-test. *-p<0.05. B. As in (A) except Hst3 stability
is measured. Time points differ as indicated.
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increase in Hst4 stability in the tco89Δ mutant, there is also a reciprocal decrease in Hst3
stability (Figure 3-13B). It is currently unclear whether this decrease is in direct response
to the enhanced level of Hst4, or it is because Hst3 is a biologically relevant substrate of
Sit4.
We next asked whether the Sit4-dependent change in Hst4 stability could be
traced to direct opposition of sirtuin phosphorylation. To probe this possibility, we
immunoprecipitated Myc-tagged Hst3 or Hst4 from WT and tco89Δ extracts and resolved
them on Phos-tag containing SDS-PAGE gels. Phos-tag is a reagent that binds
phosphorylated residues and reduces their electrophoretic mobility, allowing for more
distinct resolution of phosphorylated compared to non-phosphorylated forms of a given
protein. We observed a marked reduction in the slower migrating forms (phosphorylated)
of both Hst3 and Hst4 in wild-type extracts treated with lambda phosphatase; however,
no discernible difference was detected in the phosphorylation pattern of either sirtuin
when wild-type and tco89Δ extracts were compared (Figure 3-14A). As a control, we
repeated the experiment shown in Figure 3-14A using the downstream TORC1
phosphotarget Sch9 (Figure 3-14B). We found a dramatic downward shift in Sch9
mobility in both the lambda phosphatase treated sample, as well as the rapamycin treated
sample, confirming that the Phos-tag reagent behaves as expected. In all, these findings
identify a novel mechanism in which TORC1 inhibition promotes Sit4 activation and
site-specific histone deacetylation via stabilization of Hst4. These effects appear to occur
independently of a direct role for TORC1 in Hst4 phosphorylation status.
Hst4 Nuclear Accumulation Occurs Rapidly as a Consequence of TORC1 Inhibition
and Sit4 Activation, and Precedes the Increase in Hst4 Stability
It was previously reported that metazoan SIRT1 and SIRT2, as well as yeast Hst2
and Hst4, actively shuttle between subcellular compartments in response to starvation,
cellular stress or cell-cycle progression (summarized in Tables 1-1 and 1-2) [168, 176,
188, 222, 312]. As outlined in Chapter 1, the best-known function of Sit4 activation
downstream of TORC1 inhibition involves regulation of transcription factor localization
to coordinate the NCR response. We therefore considered whether Sit4/PP6 activity
might stabilize Hst4 by altering its subcellular distribution. Utilizing the wild-type and
tco89Δ sirtuin 9xMyc-tagged strains described above, indirect immunofluorescence
(Figures 3-15 and B-3) and quantitative analysis (Figure 3-16A) was performed as
detailed in Chapter 2. Of the five sirtuins, Hst4 exhibited the most significant alteration in
cellular localization, as diffuse staining throughout wild-type cells was considerably more
nuclear focused in tco89Δ (Figures 3-15, 3-16A, B-3D).
To determine whether the increase in Hst4 protein levels occurred before or after
the nuclear accumulation of Hst4, we repeated the experiment described in Figure
3-16A, this time including an additional wild-type sample treated with 200 nM
rapamycin for 20 minutes. Importantly, we saw that the 20-minute rapamycin treatment,
which previously had very little effect on protein levels (Figure 3-11B), was sufficient to
promote maximal nuclear accumulation of Hst4 (Figures 3-16B and B-3D). This
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Figure 3-14. Hst3 and Hst4 phosphorylation state is independent of TORC1
function.
A. Wild-type (WT) Hst3-9xMyc, tco89Δ Hst3-9xMyc, WT Hst4-9xMyc and tco89Δ
Hst4-9xMyc were grown to log phase and extracts were prepared. Hst3 and Hst4 were
immunoprecipitated from 1 mg of extract, and the sirtuin bound IgG-conjugated beads
then were treated with lambda phosphatase for 1 hour at 30°C as indicated. IP samples
were resolved on 10% SDS PAGE gels containing Phos-tag (50 μM) and evaluated by αMyc IB. Input gels were run in parallel where 35 μg extract was resolved on 10% SDS
PAGE gel without Phos-tag present. B. As in (A), except Sch9-6xHA strains were
utilized.
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Figure 3-15. TORC1 suppression drives Hst4 nuclear accumulation in a Sit4dependent fashion.
Wild-type, tco89Δ, and tco89Δ sit4Δ strains containing either no tag or a 9XMyc epitope
on Hst4 were grown to log-phase, fixed, permeabilized, and imaged using indirect
immunofluorescence as described in Chapter 2. Images are representative of at least five
biological replicates. DAPI staining denotes the nucleus and the α-Myc (FITC) tracks the
localization of Hst4.
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Figure 3-16. Hst4 nuclear accumulation occurs rapidly as a consequence of
TORC1 inhibition and precedes the increase in Hst4 protein stability.
A. Nuclear ratios of the sirtuins were determined from a series of images, as described in
Chapter 2, and graphed. Means and SDs presented are representative of five or more
biological replicates. Each replicate contained 20-40 randomly selected cells. B. Wildtype Hst4-9xMyc cells were grown to log phase and mock or rapamycin treated (300 nM
rap, 20 min) before analysis as described in (A). tco89Δ Hst4-9xMyc and tco89Δ sit4Δ
Hst4-9xMyc strains were included for comparison. Significance was determined by
pairwise Student’s t-test. *-p<0.05; **-p<0.01.
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correlated well with the timing of the acetylation response (Figure 3-1C). Finally, in a
tco89Δ sit4Δ Hst4-9xMyc strain, which displays a wild-type level of Hst4 expression and
turnover (Figures 3-11C and 3-13A), the cellular distribution of Hst4 was corrected
(Figures 3-15 and 3-16B). Therefore, Sit4 activation is required to promote Hst4 nuclear
localization and rapid histone deacetylation (within 20 minutes), and the subsequent
stabilization of this nuclear HDAC (60 minutes post-TORC1 inhibition) likely sustains
the hypoacetylation phenotype until TORC1 activity is restored.
TORC1-Dependent Histone Acetylation Does Not Impact RP Gene Transcription,
But Does Contribute to a Subset of TORC1-Regulated Biological Functions
TORC1 had been previously identified as a regulator of acetylation at the rDNA
and the RP genes, and our lab recently characterized a critical role for TORC1-mediated
H3K56ac in RNA polymerase I-dependent rDNA transcription [12, 13, 66, 140, 142].
Given this, and TORC1’s well-established link to anabolism, we next asked whether
these TORC1-regulated acetylation states contributed to the transcriptional regulation of
ribosome biogenesis. In the initial characterization of Tco89, it was reported that tco89Δ
mutants had no effect on ribosomal protein gene expression [43]. However, we chose to
revisit these claims as the authors did not present the data or identify the genes they had
assayed. Utilizing cDNA from Figure 3-12, we examined how decreased acetylation
(WT to tco89Δ), and subsequent restoration (tco89Δ to tco89Δ hst4Δ), impacted
expression of a subset of RP genes encoding both small and large ribosomal subunits. We
found that in the tco89Δ mutant, where TORC1 function is decreased (Figure B-1) and
we observe a global site-specific reduction in acetylation (Figure 3-1A), there is not a
significant effect on RP mRNA levels (Figure 3-17). The hst4Δ had a similarly
negligible effect, while tco89Δ hst4Δ resulted in a moderate yet significant reduction in
RPL23B expression (Figure 3-17).
tco89Δ mutants have been reported to enter an irreversible, growth-arrested state
following TORC1 inhibition [49]. A number of characterized physiological states and
compounds can promote this permanent growth-arrest, including nutrient starvation,
rapamycin, the DNA damaging agent hydroxyurea, and the metalloid arsenic trioxide [57,
313]. And while the ultimate cellular response is often similar, the mechanisms
underlying these effects can be very diverse [314]. We next determined if restoration of
TORC1-regulated acetylation could rescue the sensitivity of tco89Δ mutants to these
TORC1 inhibitors. Excitingly, we found that pairing an hst3Δ or hst4Δ with tco89Δ
reversed its sensitivity to low dose rapamycin (5 nM), as well as to hydroxyurea and
arsenic trioxide (Figure 3-18). These spotting data were surprisingly distinct from what
was observed with the tco89Δ sit4Δ across the same spectrum of conditions. Although
tco89Δ sit4Δ was sufficient to restore wild-type growth on hydroxyurea and arsenic, it
failed to enable growth on rapamycin (Figure 3-18).
A previous study suggested that Hst4 may be the functional ortholog of the
metazoan mitochondrial SIRT3 [176]. This study demonstrated that Hst4 localization to
the mitochondria fluctuates in response to vitamin availability (biotin), and that this effect
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Figure 3-17. Global loss of TORC1-responsive acetylation marks does not correlate
with a change in expression of a subset of ribosomal protein genes.
WT, tco89Δ, hst4Δ and tco89Δ hst4Δ cells were grown to log phase, cDNA was
synthesized from total RNA, and qPCR was performed with the primer sets indicated.
Data are the average and SD of four independent experiments and significance was
determined by pairwise Student’s t-test. **-p<0.01.
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Figure 3-18. TORC1-PP6 regulated histone acetylation is functionally significant
for a subset of TORC1-dependent processes.
WT, tco89Δ, hst3Δ, tco89Δ hst3Δ, hst4Δ, tco89Δ hst4Δ, sit4Δ and tco89Δ sit4Δ were
cultured to saturation overnight. Cells were five-fold serially diluted and spotted onto the
indicated plate media. Images were obtained after four days at 30°C.
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correlates with changes in mitochondrial protein acetylation, cellular respiration, and
reactive oxygen production. Given the similarities between the biotin signaling
mechanism, and the one we described above, we asked whether the nitrogen responsive
TORC1-PP6-sirtuin cascade may also impact mitochondrial function. To explore this
concept, wild-type, tco89Δ, hst4Δ and tco89Δ hst4Δ cells were either mock treated or
treated with a low concentration (5 nM) of rapamycin for 2 hours. Cells were then stained
with DHE to detect reactive oxygen species (ROS). TORC1 inhibition, via rapamycin
treatment or tco89Δ, had relatively little effect on ROS production relative to wild-type
mock-treated cells (Figure 3-19). In agreement with the biotin study [176], deletion of
HST4 did indeed trigger a decrease in basal ROS levels in both the wild-type and the
tco89Δ backgrounds (Figure 3-19). Considering TORC1 inhibition did not have an effect
on ROS production, it would seem that the link between Hst4 and ROS occurs
independently of our newly-characterized PP6-dependent mechanism. Still, this is an
interesting development and provides insight into another biologically relevant function
for this sirtuin.
In all, our data illustrate the existence of a novel TORC1-PP6-sirtuin signaling
cascade that coordinates the epigenetic modification of histones with changes in
environmental nitrogen availability. Further, we demonstrate that the downstream
activation of sirtuins, in response to TORC1 inhibition, plays a critical role in an array of
cellular operations, including cell cycle re-initiation following stress and DNA repair.
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Figure 3-19. Hst4 contributes to cellular ROS levels independently of TORC1.
WT, hst4Δ, tco89Δ and tco89Δ hst4Δ cells were cultured to log phase and mock or rap
treated (5 nM) for 2 hours. Cells were then washed and stained with DHE for 20 minutes
prior to analysis by flow cytometry. Data presented are the average and standard
deviations of five independent experiments. Significance was determined by pairwise
Student’s t-test. *-p<0.05; **-p<0.01.
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CHAPTER 4. HMG DISPLACEMENT OCCURS INDEPENDENTLY OF
TORC1-MEDIATED HISTONE ACETYLATION TO PROMOTE A NOVEL,
STRESS-RESPONSIVE CELL DEATH
H3K37A Mutation Correlates with HMGB Nuclear Delocalization and Is Sufficient
to Change Rapamycin from a Cytostatic to a Cytotoxic Agent
Our lab previously identified a significant and unique genetic link between
TORC1 signaling and one particular histone tail residue, H3K37 [152]. Using a library of
histone mutants in which each residue has been individually mutated to alanine [315], we
screened for altered sensitivity to the TORC1 inhibitor rapamycin. H3K37A turned out to
be the only mutant in the library that, when treated with low doses of rapamycin,
exhibited a dramatic loss of viability ([152] and Figure 4-1A). This rapamycin sensitivity
proved to be independent of histone post-translational modification however, as replacing
the native lysine with an amino acid that mimics acetylation (glutamine), or simply
restores its charge (arginine), rescued the rapamycin phenotype (Figure 4-1A, lower
panel). The only known function for H3K37 in the cell is to anchor HMGBs to chromatin
[252, 253, 316, 317]. In previous work from our laboratory, we hypothesized that the cell
death caused by TORC1 inhibition in H3K37A cells was attributable to nuclear
delocalization of HMGBs [152]. Given the findings presented in Chapter 3, we sought to
expand on this previous work to probe whether TORC1-regulated histone acetylation
may contribute to the binding of HMGBs to chromatin.
Initially, we screened for other HMGB proteins that may behave similarly to the
previously characterized Nhp10 [152]. We found that Nhp6a is also displaced from the
nucleus in H3K37A cells following transient low dose exposure to rapamycin (Figure
4-1B). Nhp6a delocalization does not occur in an H3K37R mutant (Figure 4-1B), which
fits with the fact that H3K37R cells are not sensitive to TORC1 inhibition (Figure 4-1A).
Together, this shows that there is a strong correlation between HMGB delocalization and
the overall health of the cells under TORC1-limiting conditions. Critically, while HMGB
release into the cytoplasm occurred 60 minutes post-rapamycin treatment (Figure 4-1B),
a significant increase in cell death was not observed until between 60 and 90 minutes
post-rapamycin (Figure 4-1C). These data support our hypothesis that HMGB nuclear
delocalization may drive induction of apoptosis/necrosis under TORC1-limiting
conditions, rather than simply occurring as a consequence of cell death. We next asked
whether H3K37A mutants would be less sensitive to rapamycin if Hst4 (the sirtuin
opposing TORC1-dependent histone acetylation) or Sap4 (one of the ancillary PP6
subunits critical for stabilizing Hst4 under TORC1-repressive conditions) were deleted.
hst4Δ had no effect on Nhp6a localization (Figure 4-2A), nor did hst4Δ or sap4Δ restore
cellular viability following rapamycin treatment (Figure 4-2B). Additionally, there was
no significant growth advantage for the H3K37A hst4Δ or the H3K37A sap4Δ during
transient or long-term rapamycin exposure (Figure B-4A and B-4B respectively). And
finally, H3K37A mutants plated on media containing both nicotinamide and rapamycin
did not show improved growth compared to rapamycin alone (Figure B-4C).
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Figure 4-1. The H3K37A mutation correlates with HMGB nuclear delocalization
and converts rapamycin from a cytostatic to cytotoxic agent.
A. Strains from a previously described histone mutant library [315] were grown to
saturation, five-fold serially diluted, and spotted onto YPD control plates or YPD + 20
nM rapamycin. A cartoon illustrating relevant H3 N-terminal tail residues is provided,
and H3K37 is highlighted in pink. See text for more details. B. H3WT and H3K37A cells
expressing Nhp6a-EGFP were either mock or 20 nM rapamycin treated for one hour.
Confocal microscopy images were obtained and analyzed as described in Chapter 2.
Quantification of this data is provided, with means and SDs plotted. Significance was
determined by pairwise Student’s t-test. **-p<0.01. C. H3WT and H3K37A were
cultured to log phase and then mock or 20 nM rapamycin treated for increasing lengths of
time as denoted below. Cells were stained with YO-PRO-1 and PI and analyzed by flow
cytometry. Averages and SDs are representative of three independent experiments. Data
source: personal communication with Dr. Hongfeng Chen, May 2016.

54

Figure 4-2. Partial restoration of TORC1 responsive histone H3/H4 acetylation
does not reverse Nhp6A nuclear delocalization or cell death.
A. H3WT and H3K37A expressing Nhp6a-EGFP, and the matched hst4Δ mutants, were
either mock or 20 nM rapamycin treated for one hour. Confocal microscopy images were
taken and analyzed as described in Chapter 2. Averages and standard deviations are
presented, and are representative of at least 3 independent biological replicates.
Significance was determined by pairwise Student’s t-test. *-p<0.05. B. H3K37A,
H3K37A hst4Δ and H3K37A sap4Δ were cultured to log phase and then mock or 20 nM
rapamycin treated for one hour prior to staining with YO-PRO-1 and PI and FACS
analysis. The data are the average and SD of three independent experiments. Matched
H3WT samples were analyzed in parallel (including sap4Δ and hst4Δ strains), however
there was not any detectible apoptosis or necrosis in those samples. Data source for
Figure 4-2A: personal communication with Dr. Hongfeng Chen, May 2016.
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Overall, while these data do support a functional role for H3K37 as a vital contact
residue for HMGB-chromatin binding under conditions of TORC1 inhibition, they argue
against the hypothesis that TORC1-dependent acetylation contributes to this association.
An alternative possibility could be that the TORC1-dependent chromatin changes
detailed in Chapter 3 may function in parallel with H3K37 to suppress cell death. It is
important to emphasize that we have demonstrated there is some functional redundancy
amongst the sirtuins and Saps in their effects on histone acetylation. Therefore, in the
absence of Hst4 or Sap4, additional Saps or sirtuins may partially compensate and thus,
mask their potential contributions to this process. We chose to use these strains as we
were unable to create an H3K37A sit4Δ mutant, which presumably would have had a
greater effect on acetylation, and possibly rapamycin sensitivity.
Aberrant HMGB Expression and Localization Result in Vacuolar Acidification and
Apoptotic and Necrotic Cell Death through a Novel Death Pathway
We next investigated the cell death mechanism triggered by HMGB displacement
in H3K37A mutants following TORC1 inhibition. Previously, we noticed that the
H3K37A cells displayed abnormal vacuolar morphology even prior to TORC1
suppression [152]. It was unclear at the time whether these vacuoles were dysfunctional,
or if this was simply a sign of a compensatory increase in autophagy. We speculated that
these changes in vacuole morphology may be linked to the cell death phenotype observed
in TORC1-suppressed H3K37A cells. To explore this concept, H3 wild-type (H3WT)
and H3K37A mutants were stained with CFDA, a dye which is used to visualize changes
in vacuolar pH. Confocal microscopy analysis identified significant vacuole acidification
in H3K37A mutants following 60 minute rapamycin exposure, whereas no change in pH
was detected in similarly treated H3WT cells (Figure 4-3A). Importantly, the timing of
acidification correlates with the nuclear release of HMGBs, which again, occurs prior to
significant cell death (Figure 4-1C). Vacuole acidity was quantified by flow cytometry
and steadily increased for hours in the rapamycin-treated H3K37A mutant (Figure 4-3B).
There was no discernible change in the rapamycin-treated H3WT cells over this same
period. Together, these results would suggest that cytoplasmic HMGBs may be
promoting cell death, in part, via vacuolar dysfunction.
To demonstrate this vacuolar acidification is directly attributable to HMGB
delocalization, we next asked whether aberrant HMGB expression caused a similar
constellation of vacuolar effects in an otherwise wild-type cell. To accomplish this, we
transformed H3WT cells with galactose-inducible Nhp6a or Hmo1 expression vectors.
Cells were cultured in raffinose, treated with 2% galactose for 20 minutes, and then
stained with CFDA and quantified by flow cytometry analysis. Unfortunately because
vacuolar pH is highly responsive to metabolic changes, even transient galactose induction
in minimal raffinose media led to increased acidity in the control cells, thus confounding
data analysis (data not shown). Still, because the galactose-inducible promoter is leaky,
confirmed by immunostaining for HMGB expression in the absence of galactose (Figure
B-5), we attempted the experiment in minimal raffinose media without galactose
induction. Excitingly, we were able to recapitulate the decrease in vacuolar pH by simply
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Figure 4-3. Aberrant HMGB localization results in vacuolar acidification.
A. H3WT and H3K37A cells were grown to log phase in YPD and then mock or 20 nM
rapamycin treated for 20 minutes. Cells were stained with CFDA and imaged via direct
confocal microscopy as described in Chapter 2. Arrows denote cells with increased
vacuolar acidity. B. As in (A), except rapamycin treatment was extended to 1-3 hours and
analysis was conducted by flow cytometry. C. H3WT cells transformed with control
vector or galactose-inducible NHP6A or HMO1 vectors were grown to log phase in YPRaffinose. Cells were then stained with CFDA and analyzed by flow cytometry. D.
Quantification of the average and SD of the peak CFDA fluorescence of the entire gated
population shown in (C). E. Quantification of the average cell number and SD of the
bracketed population in (C). Data are representative of five independent experiments.
Significance was determined by pairwise Student’s T-test. **-p<0.01; ***-p<0.001. Data
source for Figure 4-3A: personal communication with Dr. Hongfeng Chen, May 2016.
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deregulating HMGB expression/subcellular distribution in an otherwise wild-type cell
(Figure 4-3C, D and E). We identified a shift in total CFDA signal (Figure 4-3C,
quantified in 4-3D), indicative of a decrease in the average vacuolar pH. Additionally, we
observed a change in the overall population distribution toward a more acidic pH
(denoted by bracketed population in Figure 4-3C, quantified in Figure 4-3E).
Our time course experiments suggested that vacuole acidification occurred prior
to any significant loss of viability (Figure 4-3B). However, it remained unclear whether
the cell death downstream of TORC1-dependent HMGB displacement was directly
caused by the decrease in vacuolar pH. To address this point, we incorporated MES into
our plate media to ask whether pH buffering could rescue the H3K37A rapamycin
phenotype. We found that the H3K37A cells were significantly less sensitive to
rapamycin when cellular pH was buffered (Figure 4-4). These results further support our
hypothesis that TORC1 inhibition in H3K37A, and the resulting HMGB delocalization, is
an initiator of cell death through aberrant vacuolar acidification.
H3K37A Mutants Display Increased TORC1 Activity, Which Correlates with
Displacement of HMGBs and Can Be Reversed by HMGB Deletion
Our findings to this point illustrate a strong correlation between HMGB
delocalization and vacuolar dysfunction. We previously hypothesized that one reason the
H3K37A mutant is hypersensitive to rapamycin is that, while H3K37 serves as the main
chromatin docking site for HMGBs, TORC1-dependent histone acetylation states may
contribute to HMGB chromatin binding as well. However, the data presented in Figure
4-2 would suggest instead that TORC1 signaling and HMGB binding may function in
parallel to synergistically regulate cell survival. In the process of performing the
experiments with the H3K37A hst4Δ and H3K37A sap4Δ strains (Figure 4-2), we
serendipitously discovered that H3K37A mutants have a dramatic increase in basal
TORC1 activity as demonstrated by S6 phosphorylation (Figure 4-5A).
Recently an insightful review was published by Eltschinger and Loewith [318]
describing a series of feedback loops centered around TORC1. Given that TORC1
complex activation is tightly linked to vacuolar processes, we speculated that the nuclear
displacement of these HMGs downstream of TORC1 might alter vacuole function to
feedback and affect complex activity. Strikingly, wild-type cells transformed with
galactose-inducible HMG plasmids exhibited significantly elevated TORC1 signaling
relative to control vector expressing cells (Figure 4-5B). Additionally, we found that
genomic deletion of the HMGs previously identified as having TORC1-responsive
cytoplasmic localization (Nhp6a and Nhp10) was sufficient to reduce TORC1 signaling
in both H3WT and H3K37A backgrounds (Figure 4-5C). This effect is specific as
deletion of HMO1, a gene encoding an HMG whose nuclear localization was unaffected
by both H3K37A and TORC1 inhibition [152], had no effect on TORC1 function (Figure
4-5C). Altogether, these findings confirm that delocalization of HMGs in both H3WT
and H3K37A backgrounds, particularly the nuclear to cytoplasmic translocation of
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Figure 4-4. Buffering intracellular pH is sufficient to partially reverse the
rapamycin sensitivity of an H3K37A mutant.
H3WT and H3K37A cells were grown to log phase, five-fold serially diluted, and spotted
to indicated media conditions. Data source: personal communication with Dr. Hongfeng
Chen, May 2016.
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Figure 4-5. H3K37A mutants display increased TORC1 activity that depends on
the presence of specific HMGB factors.
A. H3WT and H3K37A cells were grown to log phase and mock or rapamycin treated
(20 nM) for 60 minutes. Extracts were prepared and analyzed by IB as indicated. B.
H3WT cells transformed with galactose-inducible, HA-tagged, HMGB expression
vectors were grown to log phase in raffinose media prior to 2% galactose induction for 20
minutes. Samples were processed and analyzed as in (A). C. H3WT and H3K37A strains
were constructed in which the indicated individual HMGB genes were deleted. Strains
were grown up to log phase in YPD and analyzed by IB as in (A).
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Nhp6a and Nhp10, is sufficient to promote vacuolar dysfunction and an overall increase
in TORC1 activity.
In all, the work presented in this chapter suggests that H3K37 does indeed serve
as a docking site for high-mobility group proteins in vivo, though whether TORC1responsive acetylation states contribute to HMGB chromatin binding is questionable.
Disruption of HMGB chromatin association results in apoptotic and necrotic cell death
marked by aberrant vacuolar pH and elevated TORC1 function.
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CHAPTER 5.

INVESTIGATING THE ROLE OF TCO89 IN TORC1

Identification of the Domain Necessary for Tco89-Dependent TORC1 Functions
Very little is known about the function of the S. cerevisiae TORC1 subunit
Tco89, and structurally, we know virtually nothing. As was mentioned in Chapter 1,
homologs have been identified in S. pombe and C. albicans, though curiously, it is
currently the only yeast TORC1 subunit without an obvious mammalian ortholog [52,
53]. There is evidence that Tco89 bridges TORC1 and the vacuole [49], coordinates
vacuolar function via Vac8 [62], and also regulates site-specific histone acetylation [66].
Previous studies summarized on the Saccharomyces Genome Database demonstrate that
tco89Δ cells have abnormal cellular physiology and budding patterns, as well as
dramatically increased sensitivity to heat, caffeine, MMS, rapamycin and salt [52, 54-60].
Allowing tco89Δ cells to reach stationary phase where nutrients are limiting, or treating
them with rapamycin, results in an irreversible cell-cycle arrest [49, 61]. These effects
demonstrate that loss of this subunit enhances cellular sensitivity to TORC1 inhibition.
Interestingly, these mutants are also described as having a decreased rate of carbon and
nitrogen metabolism [319]. We believe a better understanding of Tco89’s role within the
complex could provide insight into whether a similar subunit exists within mammals. If
so, targeting such a factor pharmacologically could greatly enhance the clinical efficacy
of mTORC1 inhibitors.
We first wanted to identify the key domains of the protein required for its
function. We constructed a series of N-terminal Tco89 truncation mutants, each
displaying a C-terminal FLAG epitope tag. Very little is currently known about the
structure of Tco89, so we utilized the PSI-PRED prediction profiling software as a guide
for where to draw our boundaries between clones (Figure 5-1A) [302]. It was our hope
that with this information we could avoid truncating in the middle of a domain, which
would likely confound our analysis. Our cloning strategy is shown in full in Figure 5-1A.
We demonstrated that all of our truncations are stable and expressed at approximately
equal levels in Figure 5-1B. While the particular blot presented in Figure 5-1B appears
to have less of clone B present, we note that this is not a consistent result. There seemed
to be a degree of fluctuation across the independent transformations which is not
currently understood, but we never observed a pattern that would suggest one clone is
more or less stable than the rest, nor did these fluctuations ever seem to correlate to a
difference in screened phenotypes.
Wild-type and tco89Δ cells transformed with control vector, a vector expressing
full-length Tco89, or various Tco89 truncations, were grown overnight to saturation.
Equivalent numbers of cells were then serially diluted and spotted onto control selection
plates, and selection plates containing rapamycin or caffeine (Figure 5-2A). The
phenotype of each mutant grown on these various TORC1 inhibitors was qualitatively
scored using a previously described method [152]. These values were averaged and are
shown in heat map format in Figure 5-2B. Clearly, there is a dramatic difference in
rapamycin sensitivity comparing fragment C to fragment D, which would indicate that
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Figure 5-1. Construction of Tco89 mutant expression vectors.
A. Diagram of cloning strategy used to create a series of N-terminal truncations of the
TORC1 subunit Tco89. Constructs contain a C-terminal FLAG epitope for visualization.
PSI/PRED prediction software was used to locate probable secondary structure, and the
software profile information is provided [302]. Predicted α helices are denoted in red and
β strands in blue. B. tco89Δ cells were transformed with control vector (CV), or vectors
containing full-length Tco89 (FL) and the truncations (A-F). Transformants were grown
to log phase under selection, and whole cell extracts were prepared and blotted for FLAG
to confirm expression. Arrows denote the seven Tco89 truncation fragments. G6PDH is
provided as a loading control.
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Figure 5-2. Identification of the functional domain necessary for Tco89dependent TORC1 functions.
A. WT cells transformed with control vector, and tco89Δ strains expressing the series of
Tco89 truncation vectors, were grown to stationary phase, five-fold serially diluted and
spotted to TORC1 inhibitory conditions as indicated. Images are representative of growth
following four days incubation. Growth on various conditions was scored on a -3 to 3
scale as described previously [305], and in Chapter 2. B. Quantification of growth
phenotype scores from (A). Data is presented as a heat map, with red indicating
decreased growth compared to wild-type, white indicating no change, and green
representing an increase in viability. Scores are the average obtained from at least five
independent transformations. C. Strains of interest from (A) were grown to log phase and
extracts were prepared. Samples were analyzed by immunoblot as indicated.
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amino acids 465-399 are critical for maintaining the cell’s ability to grow when TORC1
activity is reduced. Interestingly, a similar effect is seen with caffeine between fragments
B and C, suggesting that Tco89 may mediate the cellular response to rapamycin and
caffeine in different ways. Although fascinating, this result is not entirely surprising
given previous work that indicated rapamycin and caffeine affect TORC1 function
disparately [320], and that caffeine may inhibit TORC1 in a Tco89-dependent fashion
[62].
Finally, we explored whether the dramatic shift in spotting phenotypes observed
between fragments C and D correlated with a decline in TORC1 activity. Cells from
Figure 5-2A were grown to log phase, WCEs were prepared, and TORC1 signaling was
assessed by blotting for phosphoS6. In Figure 5-2C, we demonstrated that indeed there is
an almost complete loss of steady state TORC1 function from fragment C to fragment D,
which correlates nicely with the significant increase in sensitivity to rapamycin and
caffeine (Figure 5-2A and 5-2B). We had hoped to utilize these truncation mutants for
further phenotypic evaluation, however given that our selectable marker was auxotrophic,
and all of our processes of interest are highly responsive to nutrients, the necessity of
growing cells on defined media to select for the plasmids led to confounding results (data
not shown).
The Observed Cell Cycle Arrest in tco89Δ Upon TORC1 Limitation Is Not
Attributable to Dysregulation of Reactive Oxygen Production
We next wondered whether tco89Δ’s dramatic sensitivity to TORC1 inhibitors
could be partially alleviated by removal of an upstream negative regulator of TORC1. To
assess this possibility, we deleted the gene encoding NPR3, a Gtr1 GTPase that
suppresses TORC1 signaling. We found that loss of this negative regulator was not
sufficient to overcome the observed rapamycin sensitivity, as tco89Δ npr3Δ grew just as
poorly as tco89Δ (Figure 5-3A). This likely means that Npr3 inhibition of TORC1 occurs
upstream of tco89Δ.
Given the reported nutrient utilization phenotypes of a tco89Δ [319], and
considering that TORC1’s effect on lifespan has been suggested to occur, in part, through
mediation of mitochondrial ROS signaling [321-325], we next examined the effect loss of
Tco89 has on mitochondrial function. Previous findings demonstrated that in wild-type
cells, the transition from log phase to stationary phase is marked by a dramatic increase in
ROS levels [321]. Interestingly, tor1Δ displays increased basal levels of ROS, though
there is a negligible effect on cellular ROS as this mutant transitions from log phase to
stationary phase [321]. Early exposure to ROS in the tor1Δ is suggested to “toughen up”
the cells, a phenomena known as hormesis [326]. The combination of hormesis and the
reduction in stationary phase ROS has been hypothesized as one of the ways tor1Δ, and
TORC1 suppression in general, contributes to an increase in lifespan.
We knew that in tco89Δ, nutrient limitation, TORC1 inhibition, or simply
growing cells to saturation (late log phase) resulted in a permanent exit from the cell
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Figure 5-3. Loss of Tco89 results in adaptive ROS response similar to that
observed in tor1Δ.
A. Wild-type (WT), npr3Δ, tco89Δ and tco89Δ npr3Δ cells were grown to stationary
phase, five-fold serially diluted, and spotted onto YPD and YPD + 10 nM rapamycin.
Photos provided are representative of growth after 3 days. B. WT and tco89Δ cells were
grown to early log phase (OD~0.4) and mid stationary phase (OD~15). At both points,
aliquots of cells were stained with DHE for 20 minutes followed by flow cytometry
analysis. C. WT, tco89Δ and their corresponding mitochondrial-deficient strains (denoted
Uo) were grown to log phase, mock treated or treated with 25 nM rapamycin for 5.5
hours, washed, and spotted onto YPD.
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cycle [43, 49]. This led us to wonder what the ROS profile in a tco89Δ would look like as
the strain transitioned from log phase to stationary phase, and whether dysfunction in the
regulation of ROS production could possibly explain these cell cycle defects. Unlike
tor1Δ, the tco89Δ displayed no significant increase in log phase ROS, though it did have
a significant reduction in stationary phase ROS when compared to the wild-type cells
(Figure 5-3B). The nature of the difference between tor1Δ and tco89Δ is not readily
apparent, though given that log phase and stationary phase tco89Δ cells have nearly
identical ROS levels, we can say that the observed cell cycle exit is not due to an inability
to coordinate these ROS pathways.
Finally, we wondered whether compromising the mitochondrial genome (denoted

Uo) would have an effect on the normal growth of tco89Δ, or its response to transient
TORC1 inhibition. Wild-type, tco89Δ, and their corresponding Uo mutants were grown to
log phase, mock treated or treated with rapamycin for 5.5 hours, washed and spotted onto
YPD. The mock treated Uo mutants do tend to grow slower than the paired controls.
However there does not appear to be any TORC1-dependent difference, as the tco89Δ Uo
mutant is equally as sensitive to transient rapamycin treatment as tco89Δ (Figure 5-3C).
In total, this chapter represents the first structural assessment of the role of the
Tco89 subunit within the TORC1 complex. Through construction of a series of truncation
mutants, we identify the specific domain that is critical to allow cells to grow in the
presence of TORC1 inhibition, and demonstrate that this domain is also critical for steady
state TORC1 function. We report that the irreversible cell cycle arrest observed in
nutrient deprived tco89Δ cannot be explained solely through defects in ROS signaling as
cells transition from log phase to stationary phase. We believe these findings and tools
will inform future studies to wholly characterize Tco89, and to determine whether it has a
functional mammalian counterpart.
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CHAPTER 6.

DISCUSSION AND FUTURE DIRECTIONS

It is critical for eukaryotes, whether they are single-celled yeast or multicellular
organisms, to rapidly adjust their growth and proliferative profiles in response to
intracellular deficits or changes in their extracellular environment. Studies from a number
of labs suggest a regulatory link exists between TORC1 and the epigenome, including
work in which we characterized the TORC1-responsive acetylation of H3K56 [66].
Additionally, we know from prior studies that a correlation exists between TORC1
activity, histone acetylation, and HMGB chromatin binding [152]. At the outset of this
study, we speculated that TORC1 signaling likely regulates other histone modifications
besides H3K56ac, as it was demonstrated to mediate pan-H4 acetylation at the ribosomal
protein genes [12], and that these modifications may contribute to anchoring HMGBs to
chromatin.
TORC1 and Histone Acetylation
In Chapter 3, we significantly expanded our understanding of the upstream stimuli
linking TORC1 to the control of histone acetylation, and we gained an appreciation of the
breadth of TORC1-responsive histone modifications. Foundational studies in the field
utilized pan-H3 and pan-H4 acetyl antibodies to identify gross acetylation loss in
response to TORC1 inhibition [12, 13]. But here we characterized for the first time the
TORC1-mediated acetylation of H3K18, H3K23 and H4K12 (Figure 3-1). The
specificity we observed is quite interesting and suggests inhibition of TORC1 is not
promoting a global decrease in histone acetylation, nor is it a massive non-specific effect
due to loss of all transcription-coupled marks (H3K4me3 is intact).
One possible explanation could be that inhibition of TORC1 results in a shift in
metabolic intermediate availability, including acetyl CoA and NAD+, which feed into the
acetylation and deacetylation reactions respectively. However, we would expect that if
this were the case, the effects would be more universally observed across a multitude of
histone residues. Rather this hypoacetylation appears to be a specific, site-directed
response to decreased TORC1 function, as low-level pharmacological inhibition for a
short time (20 minutes) is sufficient to induce the effect. Considering the existing link
between TORC1 and the post-translational modification of H2A in the DNA damage
response [327], it would be fascinating to probe other acetylation states such as H2AK7,
H2AK21, H2BK11, and H2BK16, to see whether TORC1-responsive acetylation exists
on H2A or H2B as well. We believe it is likely that TORC1-dependent histone
modifications extend beyond acetylation, possibly to acylation (sirtuin substrate),
phosphorylation, methylation, sumolyation, neddylation and others. Incorporation of
mass-spectrometry based histone proteomics would provide us a more complete
understanding of the diversity of the histone post translational modifications downstream
of TORC1.
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TORC1 occupies a critical point in a pair of nutrient sensing axes. Amino acids
and carbon both feed into the TORC1 signaling pathway, and each appears to do so, in
part, through adaptive intracellular pH mechanisms [49, 80, 328]. Prior to this work,
TORC1-responsive acetylation has been investigated exclusively by using the direct
pharmacological TORC1 inhibitor, rapamycin. And while we also utilize rapamycin for
this purpose, we extend our analyses to include several additional means of suppressing
TORC1 activity. These stimuli are likely more physiologically relevant and thus, we
examined their influence on our chromatin modifications of interest.
We provide striking evidence that not all TORC1 inhibition is equivalent at the
level of acetylation, finding that nitrogen metabolism disruption (MSX), but not carbon
limitation, led to decreased acetylation of a model TORC1 residue (Figure 3-2). The data
presented argues against the previous claims that crosstalk between carbon metabolism
and TORC1 signaling is responsible for our observed epigenetic effects [328, 329].
Instead, they suggest an interesting regulatory bifurcation through which cells may tailor
their epigenome based on the specific nutrient they are lacking. There is likely a degree
of overlap between nitrogen and carbon metabolism, as inhibition of TORC1 did not
result in total ablation of our modifications of interest. Still, these findings illustrate that
nitrogen signaling plays a vital and distinct role in the dynamic regulation of key
acetylation sites. Additionally, they imply that signaling between vacuolar components
(v-ATPase, EGO complex) and TORC1 is vital for the relay of environmental energy
states to chromatin-based processes. Indeed a previous genetic screen of the yeast
deletion collection found that a number of vacuole mutants display acetylation
phenotypes [330]. We speculate that functions previously attributed to TORC1-mediated
histone acetylation, including rDNA stability and regulation of RP gene expression [12,
13], are also nitrogen specific given that the need for ribosomes and anabolic flux is
reduced under starvation conditions. However, because these studies only utilized
rapamycin to inhibit TORC1, it is impossible to be sure without delving back into those
questions using specific amino acid starvation or suppression of general nitrogen
metabolism via MSX.
In Chapter 3 we also present findings demonstrating that TORC1-dependent
histone acetylation is regulated by sirtuin histone deacetylases. This corroborates our
previous observation that deletion of HST3 and HST4 in the tco89Δ background is
sufficient to rescue H3K56ac [66]. The connection between TORC1 and the sirtuins
makes sense considering how intimately each is tied to cellular energy states. TORC1
activity is most robust during times of nutrient abundance when cell growth and
proliferation would be appropriate and advantageous, while sirtuins are most active when
energy availability is limited (low NADH concentration, elevated NAD+/NADH ratio)
[291]. The reciprocal arrangement between TORC1 and the sirtuins reported in yeast
appears to be evolutionarily conserved, as mTORC1 suppression in metazoans promotes
transcription of the SIRT4 gene [184].
Within our sirtuin results (Figure 3-10), we reported several previously
unidentified, candidate substrates for each of the enzymes: Hst1 (H4K12ac), Hst2
(H3K18ac), Hst3 (H3K18ac, H4K12ac), Hst4 (H3K18ac, H3K23ac, H4K12ac) and Sir2
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(H4K12ac). Looking over these acetyl sites, we recognized several that are downstream
of sirtuins in higher order organisms as well, including H3K18ac (deacetylated by SIRT6
and SIRT7) and H3K56ac (deacetylated by SIRT6). SIRT6 regulation of H3K18ac was
only recently identified, and was shown to occur at pericentric heterochromatin [237].
Hyperacetylation of H3K18ac in the absence of SIRT6 (which will also increase
H3K56ac) leads to transcriptional activation of the otherwise silent pericentric chromatin,
and accumulation of centromeric transcripts causes mitotic defects, genomic instability
and cellular senescence. This is fascinating considering our data linking the yeast sirtuin
Hst4, a regulator of H3K18ac, and the ability of tco89Δ cells to re-engage the cell cycle
(or evade arrest entirely) in response to TORC1 inhibition. Additionally, the SIRT7dependent regulation of H3K18ac has been reported to promote oncogenic transformation
and maintain tumorigenicity by disabling transcription of tumor suppressor genes [240,
331, 332]. Notably, it was previously reported that overexpression of SIRT1 could
complement loss of Sir2 in yeast [177].
We believe future complementation studies using vector-based human sirtuins in
yeast deletion mutants could flesh out whether the human sirtuins are also responsive to
TORC1, while highlighting which enzymes are most functionally conserved between
humans and yeast. This would also provide significant evidence of mechanistic
conservation of our described mechanism. A shortcoming of this portion is that to this
point, all of the data linking TORC1 and specific acetylation states has been genetic in
nature. Considering all the different pieces of evidence we have obtained, we are
extremely confident that this observed phenomena is biologically real. Still, our stance
would be significantly strengthened if we were to use biotinylated recombinant histones
in in vitro deacetylation assays (such as the Fluor de Lys™ assay from Enzo Life
Sciences [159]) to confirm that the sirtuins do in fact target these residues.
The PP6 Phosphatase Complex and the TORC1-Dependent “Acetylome”
Our data demonstrate that when ample nitrogen is available, TORC1 regulates
sirtuin-dependent site-specific histone H3/H4 acetylation through the suppression of the
Sit4/PP6 complex and subsequently, enhanced Hst4 protein levels. One of the most
compelling parts of this work involves how PP6 activation triggers this increase in Hst4
expression. We first investigated whether HST4 gene transcription is regulated through
the Sit4-mediated NCR stress response by deleting the Sit4-responsive transcription
factors Gln3 and Gat1. The rationale being that if Hst4 protein levels are tied to Gln3
and/or Gat1 function, deletion of these NCR components should result in a decrease in
Hst4 protein and an increase in histone acetylation. It was clear however, that this was
not the case. Loss of these transcriptional regulators did not have a positive effect on
acetylation. Likewise, deletion of the cytoplasmic anchor that mediates their cytoplasmic
localization upon nutrient stress did not promote a decrease in acetylation. We also find
that TORC1 inhibition does not result in any increase in HST4 mRNA expression, all
together suggesting that the elevated Hst4 protein levels that occur in response to TORC1
inhibition occurs independent of HST4 transcriptional regulation or changes to HST4
mRNA stability. Instead, we report a mechanism in which Sit4 activation promotes a
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rapid, cytoplasmic to nuclear redistribution of Hst4, resulting in protein stabilization and
a site-specific decrease in histone acetylation. The most important take away is timing, as
we demonstrate that maximal nuclear accumulation occurs within 20 minutes (Figure 316). Presumably, it is this population of Hst4 that promotes the immediate deacetylation
observed upon acute rapamycin treatment. The subsequent increase in protein levels does
not occur until some 40 minutes later (Figure 3-11), and we believe this stabilization
sustains the hypoacetylation phenotype until TORC1 activity is restored.
In situations where we find a TORC1-dependent increase in Hst4 levels, we also
observe a corresponding decrease in Hst3, which could suggest a regulatory balance
exists between the amount of Hst3 and Hst4 in the cell. This possibility has already been
hinted at in a work which demonstrated that the replication origin deficiencies observed
in an hst3Δ cell could be overcome by expressing Hst4 under the control of the Hst3
promoter [333]. Still, it is currently unclear as to how Sit4-PP6 activation results in Hst4
nuclear accumulation (denoted by question marks in Figure 6-1). Our Phos-tag results
(Figure 3-15) would suggest that this stabilization is not directly attributable to Sit4mediated sirtuin phosphorylation. However, we have only addressed this hypothesis with
the Phos-tag approach, as our attempts to incorporate pan-phosphorylation antibodies and
phosphostains were unsuccessful (data not shown). As a consequence, given what is
known about the turnover of Hst3, we cannot yet exclude the possibility that Sit4dependent dephosphorylation of Hst3 or Hst4 does indeed regulate their function. Still,
this leaves us to wonder about alternative explanations. Such as whether the phosphatase
may coordinate sirtuin nuclear localization through regulation of importin (Srp1) and
exportin (Xpo1) factors; the yeast carrier proteins responsible for actively chaperoning
cargo proteins in and out of the nucleus. There is precedent for this as Hst2 shuttling is
known to be regulated by Xpo1 [164]. Further, the import capacity of a mammalian
ortholog of Srp1, importin α1, has been shown to be responsive to phosphorylation and
acetylation [334].
Interestingly, it would appear that the identity of the Sit4-associated protein may
confer an additional layer of specificity to the acetylation response, as we find that loss of
Sap4 or Sap185 leads to a reduction in H3K18ac rapamycin sensitivity (Figure 3-6).
Previous work examining rapamycin and zymocin sensitivity in yeast also identified
dramatic phenotypic differences attributed to Sap association [100], though it is unclear
what exactly the Saps contribute to these processes. Given the partial rescue observed in
the sap4Δ and the sap185Δ, we speculate that these regulatory subunits are functioning at
least somewhat redundantly to bridge the interaction between the Sit4 phosphatase and its
downstream targets. Considering the high degree of conservation across this pathway,
and that mammalian sirtuins are known to actively shuttle from the nucleus to the
cytoplasm, we propose that future studies include pilot experiments asking whether
exogenous human Sit4 (PPP6C) could complement Hst4 stability and localization in a
sit4Δ cell. A similar approach could be conducted using the human Sap orthologs
(PPP6R1/2/3). If it appears these mechanisms are indeed conserved, we could attempt to
replicate these findings by monitoring acetylation in human cells with RNAi knockdown
of PPP6C, PPP6R1/2/3, or the sirtuins which have been shown to shuttle intracellularly
(SIRT1/2/3).
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Figure 6-1. Proposed mechanism.
Summary of work presented in Chapter 3 as discussed in Chapter 6. Areas requiring
further study are denoted by question marks. See text for more details.
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Finally, it seems likely that TORC1 regulation of sirtuin function could contribute
to changes in acetylation of non-histone substrates as well. The mammalian sirtuins, and
particularly SIRT1, have been shown to target chromatin-modifying enzymes (p300,
MOF, Tip60), as well as proteins involved in autophagy (FOXO1, FOXO3, LC3,
Atg5/7/8), the stress-response (NF-NB, c-Myc, HIF-1α), metabolism (LKB1, PGC-1α)
and DNA repair (Ku70, PARP1). Can we build on this information to define a TORC1responsive acetylome to better understand how aberrant mTORC1 signaling promotes
disease? Could some of mTORC1’s canonical functions (anabolism, autophagy, and
ribosome biogenesis) be partially attributed to mTORC1-dependent sirtuin localization?
In addition to the yeast orthologs of the proteins mentioned above, there are a few other
yeast candidate factors we propose evaluating in future studies.
Spt7
Previous studies identified a replicative lifespan increase in mutants of the Gcn5containing SAGA histone acetyltransferase complex [335]. This observed lifespan
extension could implicate TORC1 in coordination of SAGA function, and the fact that
this effect requires Sir2 suggests the possibility that TORC1-dependent sirtuin activity
could feed into SAGA. The Pep4-dependent processing of the SAGA subunit, Spt7,
determines whether SAGA exists as a holocomplex or a subcomplex (also known as
SLIK/SALSA) lacking Spt8 [336]. Spt7 has been shown to possess a bromodomain
whose chromatin binding is sensitive to histone acetylation [337], and Spt7 has itself
been suggested to be acetylated [163].
We speculate that TORC1 may participate in regulating SAGA chromatin binding
through coordination of H3 acetylation (Chapter 3). However, it is also possible that
TORC1 may affect Spt7 acetylation via sirtuin stabilization to influence Spt7 processing,
and SAGA composition or localization. It would be fascinating to utilize the previously
described multi-epitope Spt7 strains [338] to assess TORC1 contributions to these SAGA
dynamics. Further, we could immunoprecipitate Spt7 under same conditions and
immunoblot to determine if its acetylation state is dependent on TORC1 activity. Either
of these proposed mechanisms (histone acetylation dependent, direct effects on SAGA
via Spt7) would enable TORC1 suppression to promote initial histone deacetylation
through nuclear accumulation of Hst4, and also to feed back onto SAGA to prevent the
incorporation of new histone acetyl marks. Together, these effects maintain a
transcriptionally repressive chromatin state until environmental conditions improve.
Ifh1
Ifh1is a coactivator of ribosomal protein gene transcription, and it is found at the
RP promoters when environmental nutrient availability is sufficient to sustain growth. It
is an essential gene that, when partially inactivated, results in an extension of lifespan
marked by increased sensitivity to rapamycin and DNA damage. Gcn5 acetylates Ifh1 in
a TORC1-responsive fashion, which allows for a RP transcriptional burst following
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refeeding. Importantly, these Gcn5-dependent modifications are opposed by a subset of
sirtuins. Together, this suggests the possibility that sirtuin localization/stabilization may
communicate changes in TORC1 activity to ribosome biogenesis via Ifh1 acetylation or
SAGA function (see above). If TORC1 regulates Ifh1 acetylation through a Sit4-sirtuin
pathway, we would expect that loss of the phosphatase would render Ifh1 marks
irresponsive to rapamycin. Similarly, if the hypothesis is correct, Ifh1 acetylation should
fluctuate with MSX or nicotinamide treatment as well.
Mitochondrial proteins
Lastly, we propose examining the acetylation state of mitochondrial proteins in
response to TORC1 activity. We presented evidence in Chapter 3 that localization of
Hst4 shifts toward a more nuclear distribution upon inactivation of TORC1. At the time
we did not attempt to categorize where in the cytoplasm the mobilized Hst4 was coming
from. However, we were inspired by a recent work that demonstrated Hst4 can localize to
the mitochondria in a dynamic fashion and deacetylate mitoproteins [176], drawing
parallels between yeast Hst4 and mammalian SIRT3 (see Table 1-2).
We speculate that when TORC1 is inhibited, mitochondrial Hst4 localizes to the
nucleus. This means that not only does amino acid starvation promote deacetylation of
nuclear proteins, but it also may result in an indirect increase in acetylation of
mitochondrial proteins as a consequence of a depletion of mitochondrial-localized
sirtuins. This could have a significant consequence on cellular metabolism, oxidative
stress and mitochondrial efficiency. The possibility of a multi-organellar signaling web
connecting the vacuole, the mitochondria, and the nucleus is tantalizing. Incorporating
MitoTracker (Life Technologies) into our Hst4-9xMyc confocal studies (Figure 3-15), or
immunoprecipitating mitochondrial proteins and evaluating whether they display
TORC1-responsive acetylation, are comparatively quick and easy ways to determine
whether the proposed connection would be worth pursuing. The aforementioned biotin
study from Madsen et al. does provide us with a few candidates to work with, as they
characterized the dynamic acetylation states of specific mitoproteins in the absence of
Hst2, Hst4, or Sir2 [176]. We were able to use this data to determine which proteins are
most highly responsive to Hst4 activity, and then stratify further by which targets’
acetylation seems to be specific for Hst4 (since we know only Hst4 is significantly
relocalizing). There were a few hits that were particularly interesting and could warrant
further study.
Asparagine synthetase displayed the greatest increase in acetylation in response to
hst4Δ (30 fold), which would make sense if the TORC1-regulation of sirtuins promotes
amino acid biosynthesis to attempt to overcome starvation. Fumarate reductase was also
an interesting find as it functions in the electron transport chain, meaning that affecting
its acetylation could result in changes in ATP production from mitochondria. And finally,
isocitrate dehydrogenase is a possible candidate as well, as its p-value was very high and
it plays a critical role in the TCA cycle. TORC1-regulated acetylation of either fumarate
reductase or isocitrate dehydrogenase would suggest a linkage between environmental
nutrient status and cellular bioenergetics at the mitochondria anchored by TORC1.
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TORC1-Dependent Histone Acetylation and Anabolic Gene Transcription
TORC1 signaling is known to promote transcription of an array of anabolic genes
involved in cellular growth and proliferation. Inactivation of TORC1 during starvation
leads to reduced expression of these genes. However, the extent to which TORC1responsive histone acetylation contributes to these transcriptional dynamics remains
unclear. To date, the most well-defined links between TORC1 and anabolic gene
transcription are Sch9-dependent, yet we know that the histone acetylation response
occurs through the Tap42-associated phosphatases, specifically PP6. We wondered then
whether deleting components of our signaling pathway would result in changes to RP
gene expression.
Somewhat surprisingly, in a TORC1 mutant (tco89Δ) where we have identified
global acetylation defects, mRNA levels of select ribosomal protein genes are unaffected.
Chen et al. provide a possible explanation for this, as they report that TORC1 regulation
of the RP genes occurs in parallel with PKA [339]. This type of dual input allows for
proper coordination of ribosome biogenesis with both carbon and amino acid availability,
but also suggests that in tco89Δ, the low-level TORC1 activity (Figure B-1) paired with
functional PKA may be sufficient to maintain RP gene expression. In our previous work
characterizing TORC1-dependent rDNA transcription, we utilized H3K56A mutants,
which would theoretically ablate all H3K56 acetylation in the cell. Therefore, another
possible explanation for the lack of effect on RP gene expression could be that the low
level of basal TORC1 activity retained in tco89Δ may be able to sustain local acetylation,
and as a consequence transcription, despite the overwhelming global changes. This
hypothesis is supported by the fact that the cells show no obvious growth deficiency
under steady state conditions.
It is important to remember that TORC1’s transcriptional regulation reaches
beyond just RP genes, so it is possible that other genes will be responsive to the reduced
histone acetylation described here. Future studies incorporating ChIP-seq technology
(identify genes with TORC1-responsive acetylation) and RNA-seq (quantify changes in
gene expression in response to TORC1 inhibition) will be the foundation for examining
how these modifications influence the transcriptional process. These data sets can be
overlaid to identify genes whose acetylation patterns are TORC1-dependent and correlate
with gene expression. Single gene ChIP and RT-qPCR analysis would confirm these
findings, while also determining where on the gene (promoter/body) these modifications
are occurring. Altered histone lysine acetylation may contribute to gene expression
generally, by loosening the DNA-nucleosome contacts and enabling chromatin
decondensation. But acetylation changes may also alter the docking of chromatin
modifying complexes containing bromodomains or YEATS-domains [340, 341]. Gaining
a greater understanding of how the chromatin association of these ancillary factors
changes in response to TORC1 activity will be critical to defining how environmental
nutrient availability influence anabolism at the level of transcription. Altogether, this
information would provide significant insight into how these TORC1-responsive histone
acetylation states affect chromatin-based processes.
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Interplay between Histone Acetylation and Sensitivity to TORC1 Inhibition
tco89Δ cells are acutely sensitive to rapamycin and arsenic trioxide. Importantly,
while these compounds are often grouped together as “TORC1 inhibitors”, the cellular
response they elicit, and the way in which these signals are relayed throughout the cell,
can vary significantly [314]. The effect of rapamycin on yeast TORC1 is well
understood. FK506-associated rapamycin directly binds the Tor1 kinase via its FKBPrapamycin binding domain. Short term exposure results in transient G1-S cell cycle arrest,
while long term TORC1 inhibition results in a G0 (or quiescence) response which proves
inescapable if TORC1 function is compromised (i.e. tco89Δ). Arsenic trioxide’s effect on
TORC1 is more unclear, though the majority of its phenotypes appear to be Sch9dependent [313]. The metalloid has been reported to promote a G2-M cell cycle arrest in
cell culture models [342].
Interestingly, we demonstrate that the TORC1-PP6-sirtuin cascade delineated in
Chapter 3 may contribute to cell-cycle re-entry following certain types of TORC1 stress,
as tco89Δ hst3Δ and tco89Δ hst4Δ mutants are able to escape their reported arrests and
grow similar to wild-type cells on both rapamycin and arsenic. We note that there are
likely many other signaling molecules feeding into these processes, as tco89Δ hst3Δ or
tco89Δ hst4Δ mutants are still sensitive to higher doses of rapamycin (10 nM, Figure
3-18, top right panel). There is a precedent for Tap42-associated phosphatases regulating
the cell cycle, as it was previously shown that the nitrogen responsive, Rim15-dependent
phosphorylation of PP2A plays a critical role in cell entry and exit from quiescence
[343]. We propose that sirtuin stabilization downstream of TORC1 inhibition may
reinforce the cell-cycle exit observed in tco89Δ cells exposed to arsenic or rapamycin, in
part through chromatin deacetylation. Further, we believe that the deletion of HST3 or
HST4 in the tco89Δ background enables re-entry by promoting a hyperacetylated,
transcriptionally permissive chromatin structure, devoid of barriers to the induction of
genes required to exit cell-cycle arrest. Support for such a mechanism exists, as a similar
observation was recently described in which carbon-responsive histone acetylation
regulates transcription of the CLN3 cyclin to mediate reentry into the cell-cycle following
glucose starvation [151]. A second explanation for the phenotypic rescue observed in the
tco89Δ hst3Δ and tco89Δ hst4Δ is that, rather than loss of the sirtuins promoting exit from
the transient cell-cycle arrest, the strains may simply be unable to initiate the arrest
without these sirtuins. Previous reports have demonstrated that tco89Δ cells are also
sensitive to the DNA damaging agent hydroxyurea [57], though the high throughput
nature of the study makes it unclear as to whether treatment induces a cell cycle arrest
similar to rapamycin, or if it promotes cell death. Similar to the findings with rapamycin
and arsenic, the tco89Δ hst3Δ and tco89Δ hst4Δ strains show little sensitivity to
hydroxyurea, which we hypothesize may be explained by restoration of H3K56ac, a
chromatin mark essential for DNA repair. Indeed it has been previously shown that
mimicking H3K56ac promotes resistance to DNA damaging agents [153]. In all, we find
that preventing sirtuin activation downstream of TORC1 inhibition is sufficient to rescue
sensitivity to rapamycin, arsenic trioxide and hydroxyurea, though likely through distinct
mechanisms.
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Deletion of SIT4, the phosphatase identified as a regulator of sirtuin localization
and stabilization, was sufficient to rescue tco89Δ’s growth on hydroxyurea and arsenic
oxide. Unexpectedly though, it had no effect on rapamycin sensitivity. Resistance to
hydroxyurea is likely due once again to H3K56ac, as was alluded to above. A previous
work demonstrated that Sit4’s function in response to rapamycin is dependent on the
identity of the associated Sap protein, which certainly implies the possibility of contextspecific functions [100]. To our knowledge, nobody has ever looked at how various
TORC1 stressors affect Sit4-Sap interactions, but if arsenic and rapamycin have distinct
effects on these dynamics, it could explain the observed plating phenotypes. Another
possible explanation is that the Sit4 phosphatase, which is known to exist outside of
Tap42, has both positive and negative functions in TORC1-dependent cell growth and the
necessity of each depends on the nature of the stress. We speculate that one such positive
function may be a feedback signal from the Tap42-phosphatases, or the downstream
sirtuins, to Sch9. Indeed a similar mechanism has been identified in mammals, albeit for
a different downstream mTORC1 effector, as SIRT1 activation in response to caloric
restriction regulates the acetylation, and subsequent TORC1-dependent phosphorylation,
of S6K1 (Ypk3 in yeast) [344-347]. Sch9 activity is known to be responsive to NAD+
homeostasis [348] (an essential co-factor for sirtuins), acetylation of its upstream
regulator Sip2 [349], as well as direct phosphorylation by TORC1 [80]. Considering
aforementioned evidence, we wonder whether in response to starvation, the activation of
the Tap42-associated PP6 complex, and subsequent stabilization of sirtuins, may
feedback onto Sch9 to silence any TORC1-independent activity that may arise while
nutrients are limiting. If this were the case, in our tco89Δ sit4Δ strain, in addition to
preventing the nuclear accumulation and stabilization of the sirtuins (reversing the
hypoacetylation response), we are also allowing for low-level TORC1-independent
activation of Sch9. This could enable these mutants to grow on arsenic trioxide since the
majority of arsenic effects are Sch9 specific. However the reason why these cells do not
grow on rapamycin may be due to the lack of signal continuity, as a cell’s ability to grow
in the presence of rapamycin requires coordination of Sch9 and Tap42-associated
phosphatases. Each of these effectors are known to regulate critical responses
downstream of starvation.
In summary, the findings in Chapter 3 identify a novel signaling mechanism
through which amino acid availability is sensed by TORC1 and relayed to chromatin in
two parts. The initial PP6-dependent nuclear accumulation of Hst4 prompts rapid changes
in site-specific acetylation of H3 and H4. The subsequent increase in Hst4 protein
stability suggests that nuclear localization may shield Hst4 from proteasomal turnover.
We believe that this influx of Hst4 sustains the hypoacetylation response until the
environment is permissive for growth. Coordination of these dynamics appears to play a
vital role in at least a subset of TORC1’s biological functions.
Epigenetic Dysfunction and Cellular Transformation
It has been widely reported that a vast array of cancers display aberrant mTORC1
function. This may occur in response to loss of function in the tumor suppressor PTEN,
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hyperactivation of PI3K, deletion of TSC1/2, or other genetic lesions that act to impair
normal mTORC1 regulation. Accordingly, a sizable arsenal of mTORC1 inhibitors
(“rapalogs”) have been developed and paired with just about every therapeutic
imaginable in clinical trials. In addition to mTORC1 dysfunction, many tumors also
display altered cellular metabolism and increased nitrogen requirements [350]. These
changes would likely feed into sustaining mTORC1 activity and involve the amino acid
sensing machinery at the lysosome. With this in mind, a new approach that is gaining
traction involves targeting v-ATPase function to overcome drug resistance and prevent
metastasis in a subset of cancers, including breast, non-small-cell lung, leukemia and
sarcoma [351-357]. We speculate that at least some of the benefit observed from
inhibition of the v-ATPase results from the corresponding reduction in mTORC1
function. However our data also indicates that mTORC1-responsive acetylation is strictly
downstream of amino acids, meaning that inhibiting the v-ATPase, rather than mTORC1,
may produce discernible differences in the downstream cellular phenotype.
Indeed, a recent publication found that overexpression of the E2F1 transcription
factor results in stimulation of v-ATPase activity, lysosomal reorganization, mTORC1
activation and autophagic inhibition [358]. Interestingly however, these functions do not
overlap substantially. Activation of mTORC1 involves altered lysosomal trafficking,
while the activation of v-ATPase activity involves promoting the association of the V0
and V1 subunits [358]. The authors speculate that pharmacological inhibition of the vATPase may be beneficial in curbing metastasis in tumors overexpressing E2F1. This
study beautifully illustrates how fully understanding a signaling pathway enables a more
targeted therapeutic approach.
Considering what we now know about TORC1-mediated histone acetylation, and
given that these modifications have been tied to transcription, chromatin remodeling,
bromodomain docking, DNA repair, cell cycle progression and genomic stability, it is
clear that epigenetic dysregulation downstream of hyperactive mTORC1 could play a
significant role in disease pathogenesis. Such a relationship would explain the efficacy of
combinatorial therapies pairing mTORC1 inhibitors with sirtuin activators [359-361]. It
would be interesting to compare the epigenetic response elicited by rapamycin,
bafilomycin A1 (v-ATPase inhibitor), or a combination of the two. We believe this area
of study deserves considerable attention, as it would provide significant insight into
downstream consequences of mTORC1 dysfunction while also illuminating a poorly
understood molecular mechanism of cancer progression.
TORC1-Dependent Acetylation Does Not Contribute to HMGB Chromatin Binding
In Chapter 4, we investigated whether the TORC1-PP6-Hst4 cascade described in
Chapter 3 contributed to the seemingly TORC1-dependent chromatin association of
HMGB proteins. Previous works demonstrated that H3K36 and H3K37, on the Nterminal tail of histone H3, were critical for HMGB chromatin binding [252, 253]. We
also knew that disruption of this site in yeast (H3K37A) paired with TORC1 inhibition
led to dramatic HMGB (Nhp10) displacement and cell death [152]. We confirmed here
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that this biological response also occurs with other HMGBs, as Nhp6a shuttles to the
cytoplasm in response to rapamycin in the H3K37A strain, but not in the H3WT or
H3K37R (restores protein-protein interactions) strains. This movement precedes the
observed apoptotic and necrotic cell death, and similar timing was described for Nhp10
[152]. To this point, the behavior of Nhp6a and Nhp10 in response to H3K37 mutation
and TORC1 inhibition appear to mirror one and other.
We hypothesized that one reason TORC1 inhibition disrupts the chromatin
binding of HMGBs is that the corresponding loss of acetylation, described in Chapter 3,
may destabilize the association between HMGBs and the histone tail. Surprisingly
though, combining H3K37A with hst4Δ or sap4Δ was not sufficient to suppress the HMG
displacement or the apoptotic/necrotic cell death. We believe this is explainable by the
fact that neither of these deletions completely restore acetylation under TORC1suppressive conditions (Figures 3-6, 3-10). Unfortunately, we were unable to create an
H3K37A sit4Δ mutant, which is the combination which likely would have been the most
promising given that acetylation in a sit4Δ is almost completely irresponsive to TORC1
(Figure 3-5). It is possible that if we were to pre-treat H3K37A with nicotinamide prior
to rapamycin exposure, we may see a reduction in HMG relocalization and/or cell death.
We could pursue creating an H3K37A hst3Δ hst4Δ as well.
An important note to discuss is that until recently, HMGB1 nuclear release in
mammals was believed to occur as a consequence of necrotic cell death. Once in the
extracellular space, these proteins would function as signaling molecules to stimulate
macrophage recruitment to clear the necrotic cells [251]. However, our timing
experiments demonstrate that HMGB displacement in yeast occurs prior to induction of
apoptosis and necrosis. This result leads us to propose that the nuclear to cytoplasmic
movement of HMGs could be a contributing cause, rather than an effect, of cell death.
With this new paradigm in mind, there are suddenly many new areas of study, including
determining how the HMGs are inducing cell death (next section), and evaluating other
potential intracellular signaling functions (e.g. bioenergetics, metabolism [255]) these
molecules may possess. We can now begin to visualize a complex intracellular signaling
web, centered on TORC1, which coordinates communication between the vacuole, the
nucleus and the mitochondria to affect cell viability and lifespan.
One of the weaknesses of this section is that we do not provide unequivocal
mechanistic evidence that the HMGBs are binding H3K37. Such experimental evidence
could likely be achieved using recombinant wild-type or H3K37A containing
nucleosomes and in vitro binding assays. Additionally, we do not understand yet where
the HMGBs relocalize to following their exit from the nucleus, although this is an area
we are currently pursuing. We propose future studies examining how cells respond to
constitutively cytoplasmic/nuclear versions of these HMGBs to directly ask whether their
altered subcellular distribution is causing the cell death observed in the rapamycin treated
H3K37A cells. It would also be fascinating to pursue defining how decreased TORC1
signaling synergizes with H3K37A to cause selective cytoplasmic localization of specific
HMGBs. We have not completely ruled out the contribution of TORC1-dependent
chromatin modifications, though it seems equally plausible that localization of the
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HMGBs may be mediated via direct modification (TORC1-dependent phosphorylation,
sirtuin-dependent deacetylation, etc.); a phenomena that has already been reported in
metazoan cells [362].
Cells with Aberrant HMG Localization Undergo Massive Cell Death Characterized
by Vacuolar Dysfunction and Hyperactive TORC1
Despite finding that the TORC1-dependent histone acetylation marks likely do
not contribute directly to the association of HMGBs and the H3 N-terminal tail, we were
still very interested in characterizing the cell death that appears to be triggered in
response to their nuclear displacement. After all, these dynamics proved capable of
turning low levels of rapamycin from a cytostatic agent to a cytotoxic agent. The
potential therapeutic benefit of targeting the chromatin association of HMGBs was
apparent, and served as a driving factor for the inquiries that followed.
We first demonstrated that the cell death response triggered by HMGB
dislodgement is preceded by significant acidification of the vacuole (Figure 4-3). This
was most clearly observable in rapamycin treated H3K37A cells, however there was an
approximate two-fold increase in CFDA staining of mock treated H3K37A cells
compared to the wild type control. A similar response was observed in H3WT cells
expressing exogenous Nhp6a and Hmo1 from a plasmid. We subsequently found that
mock treated H3K37A cells, and the Nhp6a/Hmo1-expressing H3WT cells, also display a
somewhat surprising increase in TORC1 activity. It is clear this is an HMGB-dependent
response, as the H3K37A nhp6aΔ and the H3K37A nhp10Δ do not display substantially
increased TORC1 function. The idea that aberrant vacuolar pH and elevated TORC1
signaling contributes to induction of cell death is supported by the fact that buffering the
growth media was sufficient to reverse sensitivity to rapamycin (Figure 4-4).
We speculate that loss of vacuolar membrane integrity, leading to release of
hydrolases/proteases and cellular acidification, may contribute to this HMGB-triggered
programmed cell death. With the above concepts in mind, we propose that one possible
destination for these displaced HMGBs may be the vacuole. There is, in fact, precedent
for this concept. Mammalian inflammatory cells actively secrete HMGB1, and this
process involves HMGB translocation from the nucleus to the lysosome in response to its
acetylation [363, 364]. This intracellular shuttling is not limited to inflammatory cells
though, as HMGB1 has also been shown to relocalize from the nucleus to the lysosome in
the human peritoneal mesothelial cell line (HMrSV5), particularly in response to the
availability of lipopolysaccharides [365]. These parallels provide support for the
possibility that displaced yeast HMGBs are shuttling to the vacuole. This hypothesis is
readily testable through co-localization studies incorporating fluorescent HMGB tags and
vacuolar stains (FM4-64). Conversely, we could attempt to co-immunoprecipitate
vacuole surface proteins and HMGBs. It is important to note that HMGB1 movement in
mammals appears to be tied more to the secretory nature, rather than the pH, of the
lysosome. However whether these functions are truly mutually exclusive remains to be
seen.
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If we assume for a moment that the HMGBs are functioning as signaling
molecules as they move from chromatin to the vacuole, we are still left to wonder what
exactly they are doing to promote vacuole acidification and TORC1 function. One
consideration is that the activation of TORC1 could simply be a physiological response to
HMGB-mediated pH changes, which likely occur through modulation of the v-ATPase.
We believe that fluctuations in pH, to an extent, may optimize conditions for the vacuolar
proteases leading to a more active enzymatic compartment, increased protein breakdown
and nitrogen availability, and enhanced TORC1 function. And while plausible, this
hypothesis would seem to contradict work from Hughes et al. which demonstrated that as
cells replicatively age, increased TORC1 signaling results in a more basic vacuolar pH
[366]. This increase in pH, which can be reversed by inhibiting TOR, PKA or Sch9,
contributes to cellular aging and mitochondrial dysfunction as a result of defective amino
acid storage. We note that Hughes is presenting this data in a different model of aging
(replicative vs. chronological), however the link between TORC1 and vacuolar pH is
striking. Considering this, we propose an alternative explanation. The observed increase
in TORC1 signaling may be a compensatory mechanism to prevent the apoptosis and
necrosis that occurs as a result of HMGB displacement. This concept would be consistent
with our results which demonstrate that buffering the growth media partially suppresses
the cell death phenotype of H3K37A mutants treated with rapamycin. This would also be
supported by the fact that H3K37A cells grow very much like wild-type under steady
state conditions, despite vacuole morphological differences and modest HMGB
displacement.
If HMGB release from chromatin proves to be a cell-death initiation signal in
mammalian cells like it appears to be in yeast, it would certainly be an attractive
pharmaceutical target. Displacement of HMGBs at low levels appears to be tolerable, but
when paired with low-dose rapamycin, it initiates a cell death response. This observation
suggests that if HMGB1 chromatin binding could be interrupted, it may allow for
administration of reduced doses of rapamycin, which could hopefully circumvent some of
the most compromising side effects.
Mapping the Functional Domains of Tco89
In Chapter 5, we made significant strides toward understanding the yeast TORC1
subunit, Tco89. The severe rapamycin sensitivity in tco89Δ cells is marked by a
permanent exit from the cell cycle, as was discussed previously [43], and it is our hope
that a more complete understanding of the subunit’s role in the complex will lead to the
identification of a mammalian ortholog. Existence of such an ortholog seems likely given
that every other yeast TORC1 component has a mammalian counterpart. The mammalian
equivalent of Tco89 would be an attractive therapeutic target to sensitize cells with hyper
mTORC1 function to TORC1 inhibitors.
Using vectors expressing the different Tco89 fragments proved challenging when
mapping the region required for particular TORC1-dependent functions. This was due to
the need to culture the cells in nutrient-defined media to select for the plasmids. The fact
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that TORC1 activity is so heavily impacted by availability of nutrients means that many
of our phenotypes are not nearly as pronounced in synthetic complete media as they are
in nutrient rich media. This makes observing differences, and attributing them to
particular protein fragments, quite arduous. If these obstacles could be overcome, by
tweaking media conditions or integrating our mutants into the genomic locus, there are a
number of very interesting studies that could be conducted. The most straightforward of
which involve utilizing our different fragments to map Tco89’s structural and functional
contributions to TORC1. We could use co-immunoprecipitation to assess which domain
is required for Tco89 incorporation into TORC1, as well as to investigate how Tco89
affects TORC1 complex stability by using Kog1 association with Lst8 as a readout. We
have already mapped which portion is critical for regulating TORC1 function (via pS6
blot) and growth on rapamycin (Figure 5-2), and it would be interesting to follow up and
ask whether this same region (demarcated between fragments C and D) is involved in
coordinating TORC1-dependent histone modifications. Notably, an earlier study utilizing
much larger Tco89 fragments reported that residues 799-388 were responsible for
interacting with Vac8 to promote the turnover of non-preferred carbon utilization
enzymes [62]. This overlaps with our region of interest (532-399), and could provide
insight as to how Tco89 coordinates the TORC1-dependent nutrient stress response.
We are enthusiastic about the identification of this minimal portion of Tco89 as
we believe it can enlighten us to what its true function is, while also aiding in
determining which downstream proteins are participating in this diverse signal relay
system. Immunoprecipitation of a few different fragments (i.e. one that does rescue on
rapamycin compared to one that does not) paired with mass spectrometric analysis could
be incredibly powerful, enabling us to identify the physical interactions necessary for
these phenotypes. Likely hits would include members of the TORC1 complex and EGO
complex, but we speculate there are additional, yet to be determined binding partners of
significant biological relevance.
tco89Δ mutants growth arrest at the G1-S boundary and enter a permanent
quiescence-like state (yet remain viable) when exposed to rapamycin, and we would like
to understand how this response is initiated and sustained. We first wondered whether the
cell cycle defect could be explained by an inability to manage ROS production as
metabolic requirements shifted. The tor1Δ mutant is known to decrease TORC1 activity
and extend lifespan. It displays a distinct increase in log phase basal ROS but a
significant reduction (compared to wild-type) in stationary phase ROS. These effects on
reactive oxygen have been identified as potential explanations for the observed increase
in lifespan of TORC1 mutants, which led us to investigate whether tco89Δ was deficient
in these mitochondrial-based processes. Our data demonstrate that unlike tor1Δ, tco89Δ
does not undergo a significant increase in log phase ROS. Though both mutants share a
significant reduction in stationary phase ROS compared to the wild-type. It is currently
unclear what is occurring in the tco89Δ strain, as it appears that ROS levels have been
completely uncoupled from these metabolically distinct stages of growth. We speculate
that deregulation of sirtuin-dependent acetylation of mitochondrial proteins, as discussed
earlier in this chapter, may contribute to the relatively stagnant ROS production in
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tco89Δ. This would be consistent with our previous result that showed TORC1-dependent
H3K56ac is responsive to deletion of TCO89 but not TOR1 [66].
Looking ahead, we are interested in investigating whether cellular growth and
proliferation is sensitive to nutrients throughout the cell cycle, or if there is a defined
window of time to arrest, after which the cell is committed to division regardless of
nutrient availability. If we used D-factor (G1) and nocodazole (G2-M) to arrest cells, then
released them into media containing rapamycin and analyzed their cell cycle profile via
flow cytometry, we could begin to understand this TORC1-dependent regulatory signal.
For example, following D-factor arrest, if tco89Δ cells exposed to rapamycin pass
through S-phase and G2-M to finish their current cell division, it would suggest a brief
window between mitosis and G1 at which cells assess their environmental conditions. If
true, we would expect that cells arrested with nocodazole and released into rapamycin
would complete mitosis and then enter G0.
In terms of sustaining the arrest, one possible explanation is that Tco89
coordinates the dynamic association of Rho1 and Tap42 to TORC1. This intricate
relationship is known to regulate the stress response [50]. In the absence of Tco89, cells
grow normally under steady state conditions, but we speculate that once the stress
response is initiated (i.e. rapamycin), it cannot be turned off. This leads to the permanent
cell cycle arrest, despite cells retaining viability. This could be studied by labeling and
co-immunoprecipitating Kog1 and Rho1, and Kog1 and Tap42 in the absence and
presence of Tco89. We could then ask whether disruption of the Rho1 stress response
prevents rapamycin effects on acetylation. Finally, we could examine how the sirtuins fit
into all of these functions since we know deletion of HST3 and HST4 is sufficient to
promote growth on low-level rapamycin.
We acknowledge there is still considerable work to be done, but the potential of
this project excites us. Undoubtedly, with persistence this avenue will prove fruitful. The
trials outlined here have equipped our lab with a unique set of tools and information that
we believe will soon lead us to the most comprehensive mechanistic and structural
understanding of Tco89 to date.
Closing Remarks
It is becoming increasingly clear that the pathologies attributed to mTORC1
dysfunction, including metabolic disorders, cancer, and cardiovascular disease, likely
possess a degree of epigenetic deregulation that far exceeds what was previously known.
While this dissertation focused on a single post-translational modification, on a defined
series of histone substrates, there are almost certainly many more TORC1-dependent
histone post-translational modifications that have yet to be discovered. We have
speculated on a few potential non-histone acetylation targets earlier in this chapter as well
(Ifh1, Spt7, mitochondrial proteins). Given the involvement of PP6, a phosphatase known
to regulate a number of downstream TORC1 effectors, there is a likelihood that TORC1
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activity could be translated into any number of epigenetic modifications beyond just
acetylation, including methylation, phosphorylation, and ubiquitination.
The scientific funding and publishing bodies in this country have embraced highthroughput sequencing techniques, which are costly, laborious to interpret for nonbioinformaticians, and the results of which are often difficult to independently replicate.
These technologies are immensely powerful, and they have led to some of the most
compelling evidence of an epigenetic component to cancer; somatic mutations leading to
an H3K27M substitution that drives gliomagenesis [367]. But the work presented in this
dissertation illustrates how molecular biology is still a critical piece of the puzzle. There
are reasons why combinatorial therapeutic approaches work but often times in the world
of chemical screening and mouse modeling, the actual biology gets lost. If we understand
how a signaling mechanism works under physiologically normal conditions, we know
where to look when things begin to go awry.
It has truly been an honor working in such an elite, dynamic, rapidly expanding
field with fantastic colleagues over the past five years. I look forward to seeing where the
epigenetic community goes in the months and years to come.
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APPENDIX A. SUPPLEMENTAL TABLES
Table A-1.
Strain
BY4741
gat1Δ
gln3 Δ
hda1Δ
npr3Δ
ppg1Δ
pph3Δ
rpd3Δ
sap155Δ
sap185Δ
sap190Δ
sap4Δ
sch9Δ
sit4Δ
tco89Δ
tpd3Δ
ure2Δ
H3G34A
H3V35A
H3K36A
H3K37A
H3K37Q
H3K37R
H3P38A
H3H39A
H3R40A

List of strains used in this study.
Genotype
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741
BY4741; gat1Δ::KanMX
BY4741; gln3Δ::KanMX
BY4741; hda1Δ::KanMX
BY4741; npr3Δ::KanMX
BY4741; ppg1Δ::KanMX
BY4741; pph3Δ::KanMX
BY4741; rpd3Δ::KanMX
BY4741; sap155Δ::KanMX
BY4741; sap185Δ::KanMX
BY4741; sap190Δ::KanMX
BY4741; sap4Δ::KanMX
BY4741; sch9Δ::KanMX
BY4741; sit4Δ::KanMX
BY4741; tco89Δ::KanMX
BY4741; tpd3Δ::KanMX
BY4741; ure2Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3G34A
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3V35A
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K36A
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37Q
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37R
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3P38A
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3H39A
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3R40A
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Source
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
OPEN Bio
[315]
[315]
[315]
[315]
[315]
[315]
[315]
[315]
[315]

Table A-1.
Strain
H3WT
YNL387
YNL389
Y3032
Y3033
Y3034
Y3035
YNL251
YNL487
YNL502
YNL516
YNL517
YNL519
YNL541
YNL564
YNL566
YNL583
YNL612
YNL614
YNL622
YNL670
YNL676
YNL678
YNL681
YNL685
YNL687
YNL689
YNL698
YNL700
YNL714
YNL716

(Continued).
Genotype
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX
hst3Δ::NAT
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX
hst4Δ::NAT
W303-1A tap42Δ::HIS3 pRS415-tap42-11
W303-1A tap42Δ::HIS3 pRS414-TAP42
W303-1A tap42Δ::HIS3 pRS414-tap42-106
W303-1A tap42Δ::HIS3 pRS414-tap42-109
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Sch9-6xHA::NAT
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
rpd3Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
hst1Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
sir2Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
hst2Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::HphNT1
pnc1Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 ρMATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX ρMATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
npr3Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst49xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
sit4Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT
hda1Δ::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst39xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst1-9xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst19xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst2-9xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Sir2-9xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Sir29xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst3-9xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst29xMyc::KanMX
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KanMX
tco89Δ::NAT (MATED HAPLOIDS/SPORULATED)
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::HYGRO
sit4Δ::KANMX
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Source
[315]
[66]
[66]
[309]
[309]
[309]
[309]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]
[304]

Table A-1.
Strain
YNL718
YNL775
YNL776
YNL778
YNL780
YNL465
YNL467
YNL490
YNL491
YNL512
YNL514
YNL595
YNL596
YNL653
YNL655
YNL671
YNL674
YNL710
YNL722

(Continued).
Genotype
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::HYGRO
sit4Δ::KANMX tco89Δ:HphNT1
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KANMX
sap4Δ::HYGRO
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KANMX
sap4Δ::HYGRO tco89Δ::NAT
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT
sch9Δ KANMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT hmo1Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A hmo1Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT nhp10aΔ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A nhp10aΔ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT nhp6aΔ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A nhp6aΔ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT NHP6A-EGFP::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A NHP6A-EGFP::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT sap4Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A sap4Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A hst4Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT hst4Δ::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37R NHP6A-EGFP::KanMX
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT NHP6A-yeGFP::HYGRO
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Source
[304]
[304]
[304]
[304]
[304]
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study

Table A-1.

(Continued).

Strain

Genotype

Source

YNL723

MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A NHP6A-yeGFP::HYGRO
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3WT hst4Δ::KanMX NHP6A-yeGFP::HYGRO
MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0
can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]ura3Δ H3K37A hst4Δ::KanMX NHP6A-yeGFP::HYGRO

This Study

YNL724
YNL725
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This Study
This Study

Table A-2.
Parent
pRS416
pJU790
pJU855
pRS416
pRS416
pRS416
pRS416
pRS416
pRS416
pRS416
pRS416
pRS416

List of plasmids used in the study.
Vector/Insert
pHmo1 Gal-HA
pNhp6A Gal-HA
pSCH9-6xHA
pSCH9-6xHA (T723A, S726A, T737A, S758A, S765A)
pSCH9-6xHA (T723D, S726D, T737E, S758E, S765E)
pSit4FL FLAG
pTco89 N-term Myc full-length
pTco89 C-term FLAG full-length
pTco89 C-term FLAG Frag A
pTco89 C-term FLAG Frag B
pTco89 C-term FLAG Frag C
pTco89 C-term FLAG Frag D
pTco89 C-term FLAG Frag E
pTco89 C-term FLAG Frag F
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Source
Open Bio GAL1 collection
Open Bio GAL1 collection
[80]
[80]
[80]
This study
This study
This study
This study
This study
This study
This study
This study
This study

APPENDIX B. SUPPLEMENTAL FIGURES

Figure B-1. TORC1 inhibition over a range of rapamycin treatment conditions
compared to a tco89Δ mutant.
WT and tco89Δ were grown to log phase and then mock treated, or treated with 25 nM or
300 nM rapamycin. Treatments shown represent resulting TORC1 activity following 20
and 60 minutes inhibition.
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Figure B-2. Control experiments for Sch92D3E expression vectors.
A. sch9Δ cells were transformed with control vector (CV) or expression vectors
containing various forms of Sch9 (see text for more details). Strains were grown in
selective media to log phase and extracts were prepared and blotted to measure
expression of mutant Sch9. G6PDH is included as an additional loading control. B.
Strains from (A) were grown to stationary phase, five-fold serially diluted, and spotted
onto selective media with a wide range of rapamycin concentrations. Plates with
galactose and glycerol as the sole carbon sources are included as well. C. Wild-type
Maf1-9xMyc and sch9Δ Maf1-9xMyc cells were transformed with the vectors from (A).
Cells were grown to log phase, treated with 300 nM rapamycin for 60 min, and extracts
were prepared. Samples were resolved on an 8% PAGE gel and blotted as shown.
Reprinted with permission [304]. Workman, J.J., H. Chen, and R.N. Laribee,
Saccharomyces cerevisiae TORC1 Controls Histone Acetylation by Signaling Through
the Sit4/PP6 Phosphatase To Regulate Sirtuin Deacetylase Nuclear Accumulation.
Genetics, 2016.
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Figure B-3. Sirtuin relocalization in response to TORC1 inhibition.
A-E. WT or tco89Δ strains, containing 9XMyc epitope tagged sirtuins, were treated as
indicated at log phase, fixed, permeabilized, and imaged by indirect immunofluorescence
as described in the Chapter 2. Images are representative of at least three independent
biological replicates, and are a subset of the quantification shown in Figure 3-16. DAPI
staining denotes the nucleus and the green channel (FITC-conjugated secondary to αMyc) tracks the localization of the sirtuins.
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Figure B-3.

Continued.
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Figure B-3.

Continued.
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Figure B-4. Disruption of TORC1-responsive histone acetylation has no effect on
H3K37A sensitivity to rapamycin.
A. H3WT, H3K37A, H3WT hst4Δ, H3K37 hst4Δ, H3WT sap4Δ and H3K37A sap4Δ
were grown to log phase. Samples were mock treated or treated with rapamycin (25 nM
or 300 nM) for 5.5 hours or 24 hours as indicated. Following treatment, pellets were
washed with sterile water and spotted onto YPD plates as described in Chapter 2. B.
Strains from (A) were grown to stationary phase and spotted onto YPD and YPD 10 nM
Rap plates. C. H3WT and H3K37A cells were grown and spotted as in (B) to the plate
media denoted. Photos are provided for rapidly growing strain/media combinations at 2
days, and at 6 days for the more sensitive pairings.

117

Figure B-5. Galactose-inducible HMGB expression vectors promote aberrant
protein levels and distribution of Hmo1 and Nhp6A even prior to addition of
galactose.
H3WT cells were transformed with control vector, or galactose inducible expression
vectors containing HA-tagged Hmo1 or Nhp6A. Strains were grown to log phase in
synthetic complete raffinose media, and then mock treated or induced with 2% galactose
for 20 minutes. Cells were fixed, processed by indirect immunofluorescence, and imaged
by confocal microscopy, as described in Chapter 2. Images are representative of three
independent experiments. DAPI staining denotes the nucleus and the green channel
(FITC-conjugated secondary to α-HA) marks the localization of the HMGBs.
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